Patent Grant
11672904
The present invention, in some embodiments thereof, relates to a system for extending and/or protecting a needle and particularly, but not exclusively, to a system to automatically retract a needle of an auto-injector when the injector is removed from an injection site.
U.S. Pat. No. 9,149,575 apparently discloses, “An apparatus (110) includes an activation mechanism (20) and a safety latch (122). The activation mechanism is operative to deploy a needle (116) to protrude out of a housing (112), the needle (116) having a longitudinal axis. The safety latch (122) is movably mounted on the housing (112) and formed with a needle opening (129) to allow the needle (116) to pass therethrough. The safety latch (122) has a first position wherein the needle (116) is aligned to pass through the needle opening (129) and a second position wherein the safety latch (122) is moved with respect to the housing (112) such that the needle (116) is blocked from movement in a direction parallel to the longitudinal axis thereof by a portion of the safety latch (122) distanced from the needle opening (129).”
U.S. Pat. No. 7,530,964 apparently discloses, “A needle device has a needle retraction mechanism that retracts the needle upon removing the device from the skin surface (either intentionally or unintentionally). Once the needle is retracted, the device is rendered inoperative. The needle can be further made inoperative by bending it when one attempts to reuse the device. In another embodiment, a needle opening formed in the base of the housing can be covered to render the needle inoperative when one attempts to reuse the device. In another embodiment, the needle device instead has a needle shield that automatically covers the needle after use.”
U.S. Pat. Nos. 8,915,882, 6,500,150, 6,824,529, and 6,843,782, apparently disclose a drug delivery device having a base member defining a skin-contacting surface, a syringe serving as a reservoir for the drug, and means for expelling drug from the syringe. The syringe is connected to the base member such that the longitudinal axis of the syringe is substantially parallel to the skin surface. A delivery needle is in communication with the syringe. The needle has an angled bend, which directs the tip of the needle substantially perpendicular to the skin-contacting surface. In use, the tip of the needle is adapted to penetrate the skin of the subject.
For such relatively slow release, an automatic expulsion device has also been suggested. U.S. Pat. No. 5,858,001 discloses a liquid drug delivery device adhered to the skin of a subject by a base member defining a skin-contacting surface having an adhesive coating. A columnar cartridge serves as reservoir for the drug and is incorporated in a housing, which is connected to the base member such that, in use, the longitudinal axis of the cartridge is disposed substantially parallel to the skin-contacting surface. A delivery needle communicating in use with the interior of the cartridge penetrates the skin of the subject when the housing snaps downward relative to the base member. This action also causes the actuation of a citric acid/sodium bicarbonate gas generator, which generates a gas to move a piston within the cartridge, compressing the drug compartment. This compression causes a stopper to be penetrated by a conduit in communication with the delivery needle, allowing the drug to be ejected from the compartment through the needle and into the subcutaneous tissue of the subject.
If using an injector device then the syringe cartridge may be preloaded and needs to be kept sterile during the process of locating it in the injector. U.S. Patent Publication No. 20140163526 discloses an automated injection device, which may be loaded with a standard type syringe and/or hypodermic needle. Optionally the syringe may be preloaded. The syringe may be loaded into the injector in a sterile state with needle cover in place. The injector includes a fastener, such as an adhesive base. The fastener may assist a user to hold the injector steady on the skin of a patient for an extended period. For example, the injector may be used to give injections of volume ranging between 0.5 and 3.0 ml over a time period ranging between 30 seconds and 10 minutes.
U.S. Pat. No. 8,603,028 relates to a “handheld injection device includes a first housing having a first axis and a second housing having a second axis. In one embodiment, the second housing is configured to support a needle. In one embodiment, the first axis and a second axis form an adjustable angle between about 180 degrees and about 90 degrees.”
Additional background art includes U.S. Pat. No. 6,189,292. U.S. Patent Publication No. 20130253434, U.S. Patent Publication No. 2009/093,792, U.S. Pat. No. 7,967,795 U.S. Patent Publication No. 20140194854.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
According to an aspect of some embodiments of the invention, there is provided a system for shielding a needle as an injection device is removed from an injection site: a base including a contact surface having an adhesive for attachment to an injection zone; a tip of a needle movable between an exposed position on a first side of the contact surface to a shielded position on an opposite side of the shielding surface; a lock inhibiting movement of the tip from the exposed position to the shielded position a body movably attached to the base, movable between a first position and a second position distanced from the first position relative to the contact surface; the body linked to the lock to engage the lock to inhibit the movement of the tip from the exposed position to the shielded position when the body is in the first position and the body disengaging the lock to allow movement of the needle tip for the exposed position to the shielded position.
According to some embodiments of the invention, the in the second position, a center of mass of the body is further from the contact surface than in the first position.
According to some embodiments of the invention, the base is positioned between the contact surface and the body of the injector and wherein the body is movable between the first position near the base and the second position distanced from the base.
According to some embodiments of the invention, the system further includes a biasing member biasing the body toward the second position.
According to some embodiments of the invention, the system further includes a retainer that retrains the body in the first position during drug delivery.
According to some embodiments of the invention, the retainer is configured to release the body to the second position in response to pulling the body away from the contact surface of the base.
According to some embodiments of the invention, the retainer includes a second contact surface and a second adhesive such that when the contact surface of the base is attached to an injection zone and the body is in the first position, the second adhesive retains the body in the first position by adhesion.
According to some embodiments of the invention, the second adhesion surface is flush to the adhesion surface of the base when the body is in the first position such that when the body is in the first position and the contact surface of the base is in contact with an injection site on a skin of a subject, the second contact surface also contacts the skin of the subject.
According to some embodiments of the invention, the body is configured to encourage pulling the body away from the injection surface from a position closer to the second contact surface than to the injection zone.
According to some embodiments of the invention, the system further includes an opening in the base and wherein the needle tip is aligned with the opening such that the needle tip passes through the opening when the needle moves from the exposed position to the shielded position.
According to some embodiments of the invention, the needle is aligned with the opening both when the body is in the first position and when the body is in the second position.
According to some embodiments of the invention, the system further includes a sterile needle cap and wherein the opening is large enough for the sterile needle cap to pass therethrough.
According to some embodiments of the invention, the system further includes a stored energy source and wherein the movement of the needle tip is powered by the stored energy source.
According to some embodiments of the invention, the body is shaped and sized for grasping by a human hand, such that grasping the body and pulling it away from the contact surface causes the moving of the body from the first position to the second position.
According to an aspect of some embodiments of the invention, there is provided a method of preventing a stick hazard from a needle tip of a drug delivery device, the device including a body, a skin contact surface, a needle and a lock fixing an orientation of the needle tip with respect to the skin contact surface, the lock including interlinked components attached to the body and the skin contact surface, the method including: Adhering the skin contact surface adhered to injection surface with the needle tip locked protruding from the delivery device into the injection surface; Releasing the lock in response to a reorientation of the interlinked components resulting from a movement of the body relative to the skin contact surface while the skin contact surface remains adhered to the injection surface.
According to some embodiments of the invention, the needle tip is biased to retract through an opening in the contact surface, the method further including, retracting the needle tip in response to the unlocking.
According to some embodiments of the invention, the method further includes pulling the body away from the skin contact surface in order to cause the movement.
According to some embodiments of the invention, the body is adhered to the injection surface to inhibit movement of the body away from the skin contact surface further including Overcoming the adhering of the body to the injection surface by means of the pulling.
According to some embodiments of the invention, the method further includes Biasing the body away from the skin contact surface.
According to some embodiments of the invention, the movement of the body relative to the skin contact surface is in a direction away from the skin contact surface.
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
The present invention, in some embodiments thereof, relates to a system for extending and/or protecting a needle and particularly, but not exclusively, to a system to automatically retract a needle of an auto-injector when the injector is removed from an injection site.
Overview
An aspect of some embodiments of the current invention relates to preventing exposure of a needle of an injector by protecting a needle before a skin contact surface of the injector is removed from an injection surface. For example, a body of the device may be disengaged from the skin contact surface as the device is removed. Disengagement optionally achieves and/or triggers protection of the needle of the injector before the skin contact surface is removed from the injection site.
In some embodiments, an exposed needle is moved to a shielded location when body of the device is moved relative to the injection site and/or a skin contact surface of the device. For example, the body may be moved away from an injection site and or the skin contact surface. For example, the device may include a body (for example including a housing and/or a chassis) that moves with respect to an attachment interface. For example, the body may move from a first location to a second location further away from a contact surface when the shortest distance between the center of mass and the contact surface is larger from the second position than from the first position. For example, the body may move from a first location to a second location further away from an injection site when the shortest distance between the center of mass and point through which the needle tip passes across the contact surface is larger from the second position than from the first position.
An attempt to tamper and/or remove the device from the injection location while a needle tip is exposed optionally causes retraction of the needle into a protected location. For example, the distance of relative movement between the injection site and/or skin contact surface with respect to the body of the device at their closest points may range between 0 to 0.3 mm and/or between 0.3 to 1 mm and/or between 1 mm to 3 mm and/or between 3 mm to 10 mm and/or between 10 mm to 30 mm. Alternatively or additionally, the body may pivot with respect to the injection and/or the skin contact surface to an angle ranging between 0 to 2 degrees and/or between 2 to 6 degrees and/or between 6 to 12 degrees and/or between 12 to 24 degrees and/or between 24 to 45 degrees when the needle retracts. Optionally, the needle may be locked into the protected position. Optionally, movement of the needle to the protected position may be irreversible.
In some embodiments, a sharp hazard may remain covered in many and/or all stages of operation of the device. For example, a needle may be deployed out of a base of a device while the base of the device is attached to an injection site (after the base is connected to the injection site). For example, the needle may be protected while the base remains attached to the injection site (e.g. before the base is removed from the injections site). Optionally, the base may surround the injection site while it is attached thereto. In some embodiments, the base of the device and/or activation may be configured to discourage operation while the base is not connected to the injection site. For example, operation of the device may include placing an adhesive contact surface against an injection site and/or pushing the body of the device toward the contact surface. For example, a user's hesitancy to dirty himself with the adhesive may discourage casual initiation and/or unintentional initiation of the device.
In some embodiments, an injection surface may include a skin surface of a subject. In some embodiments, an injection site may include a site for injecting a pharmaceutical into a subject. Alternatively or additionally, an injection surface may include an artificial surface for demonstrating the device. Alternatively or additionally, an injection surface may include an artificial surface for demonstrating the device.
Alternatively or additionally, an injection surface may include a liquid reservoir in piece of machinery (for example for injecting dye into a printer cartridge).
In some embodiments, a skin sensor and/or contact surface may pivot when an injector is pushed toward an injection site. Optionally, the needle insertion will include pivoting of a cartridge and/or needle assembly. For example, the two pivoting systems may be in opposite directions such that the needle may be oriented at a predetermined angle to the base (for example perpendicular) and/or the angle may be changed when the base is collapsed (for example, due to pushing the device onto the injection site).
Optionally, when the needle is inserted, pivoting of the needle assembly and/or cartridge may partially and/or fully return the needle to the original orientation.
In some embodiments, the base may serve as a proximity and/or skin sensor for stopping and/or protecting the device. For example, when the device is removed from an injection site, the base may be distanced from the body of the injector (for example the housing and/or the chassis and/or the cartridge of the device). Movement of the base with respect to the body of the injector optionally triggers needle protection and/or stops discharge of the drug.
In some embodiments a surface area of a base of the device and/or a skin contact surface thereof and/or an adhesive surface thereof may range between 1 to 5 cm2 and/or 5 to 25 cm2 and/or between 25 to 250 cm2 and/to between 250 to 1000 cm2 and/or between 1000 to 5000 cm2. The base optionally includes between 10 to 70% of the surface area of contact of the device with the skin of a user and/or between 70 to 90% of the surface area of contact of the device with the skin of a user and/or between 90 to 100% of the surface area of contact of the device with the skin of a user.
In some embodiments, a needle opening in base of the device may be large enough to insert and/or remove a sterile needle cover. For example, the width of the opening may range between 1 mm to 2 mm and/or between 2 mm to 4 mm and/or between 4 mm to 10 mm. The cross sectional area of the opening may range for example between 1 to 4 mm2 and/or between 2 to 16 mm2 and/or between 16 to 100 mm2.
In some embodiments, the base of the device is biased towards the body of the device. Alternatively or additionally, the base of the device may be biased away from the body of the device. Optionally, the device may have a retaining mechanism to keep the base from extending away from the body of the device. For example, the retaining mechanism may include an adhesive surface that adheres to the skin of a user and/or keeps the body of the device close to the injection site and/or close to the skin contact surface of the base.
In some embodiments, the force for overcoming the attachment (for example adhesion) of the base to an injection site (for example by pulling the base directly away from the skin surface of a subject) may range of between 0.1 to 1 Newton and/or between 1 to 5 Newtons and/or between 5 to 15 Newtons and/or between 15 to 50 Newtons and/or more. In some embodiments, the force to overcome the retainer that keeps the base close to the body of the device (for example adhesion of the housing to an injection site) for example by pulling the body directly away from the skin surface of a subject may range between 0.1 to 1 Newton and/or between 1 to 5 Newtons and/or between 5 to 15 Newtons. In some embodiments, a force for overcoming the retainer that keeps the base close to the body (for example adhesion of the housing to an injection site) may be for example between 0.1 to 10% and/or between 10% to 25% and/or between 25 to 75% of the force to overcome the attachment of the base to the injection site. In some embodiments, a force may bias a skin contact surface away from a body and/or a chassis of the injector. For example, the biasing force at the location of greatest movement between the contact surface and the body may range between 0.1 to 0.5 Newton and/or between 0.5 to 2 Newtons and/or between 2 to 5 Newtons and/or between 5 to 10 Newtons.
In some embodiments, a base of an injection device may include an adhesive skirt. For example, the adhesive skirt of the base may extend beyond an area where the adhesive is attached to the base between 1 mm to 5 mm and/or between 10 mm to 50 mm. In some embodiments, a base of an injection device may include an adhesive skirt. In some embodiments, a skin contact area of an injector not on the base may include an adhesive skirt. For example, the adhesive skirt of skin contact area not on the base may extend beyond an area where the adhesive is attached to the injector between 0.1 mm to 1 mm and/or between 1 mm to 5 mm. In some embodiments, the adhesive skirt on the base may extend ranging from 10% to 50% and/or from 50% to 250% and/or from 250% to 1000% or more further than the length to which a skirt extends on another skin contact surface of the injector.
In some embodiments a base in movably mounted to a chassis and/or a housing of the injection device. For example, the base may be pivotally mounted thereto.
Optionally a needle assembly and/or the base are movably mounted to the same component. For example, the needle may be mounted on a pivoting arm and/or plate pivoting from one side of a component (for example a chassis) and/or the base may pivot from an opposite side and/or in an opposite direction. For example, when both the needle and the base are collapsed to the body of the device (e.g. the needle extended through an opening in the base and the base collapsed to the chassis) the relative orientation of the needle to the base may be the same as when the basis and needle plate are moved away from the base (for example the needle is retracted and the base is extended away from the chassis).
An aspect of some embodiments of the current invention relates to performing automated initiation of an injection device and/or protection of a sharp needle by user intuitive actions. In some embodiments, an intuitive user interface allows a user with limited preparation and/or knowledge to operate a device based on untrained assumption and/or actions. Optionally an automated user interface performs actions that might arouse avoidance behavior in an unintuitive manner. Optionally, a user interface operates properly even when a user's untrained assumptions lead him to avoid proper activation of the device and/or lead him to act unpredictably and/or perform acts out of order.
In some embodiments, an injector may be activated by simple intuitive acts. For example, initiation may include placing an easily recognizable skin contact surface (for example a flat surface and/or a surface including an adhesive) onto an injection site and/or pushing the body of the injection device towards the injection site and/or depressing an activation button.
In some embodiments, actions that arouse natural avoidance like needle insertion are not a direct result of an intuitive act. Optionally, needle insertion may not occur as a direct mechanical consequence of the user pushes the body towards the skin. For example, needle insertion may be performed automatically by an actuator system. The actuator may optionally be triggered upon proper placement of the injection device onto the skin and/or upon a command (for example pushing a button) and/or through an automated and/or timed control system.
In some embodiments, a needle is automatically protected when a user pulls an injector away from an injection site.
In some embodiments, activation of an injector may require performance of an ordered series of actions. For example, the device may not be activated by a simple act that may be performed inadvertently. For example, the device may be activated by first removing a protective cap and/or then placing a contact surface against the skin and/or then pushing the device into place on the skin and/or then depressing an activation button. Optionally the device will not be activated by performance of only a portion of the actions and/or performance of actions out of order.
In some embodiments, the system will be insensitive to an actions not part of the proper initiation procedure and/or will be insensitive to an act performed out of the prescribed order. For example, an injector may not be affected (for example not activated and/or not disabled) by engaging of an activation switch before proper placement on the injections site. Alternatively or additionally, some improper actions and/or action performed out of order may block activation of the device.
In some embodiments, an injector device may include a user interface.
Optionally the user interface is designed to encourage intuitive and/or proper use of the injector. For example a status indicator and/or a control (for example an activation button) may be located opposite the skin contact surface such that when the contact surface is against the skin, the user sees and/or can reach the user interface.
Alternatively or additionally, the placement of the user interface may encourage the user to hold the injector in a proper way for example for proper placement and operation of the device.
In some embodiments, a needle extension and/or protection system in accordance with the current invention may be included in a patch injector and/or a stabilized pen injector. For example, a patch injector may include a drug reservoir (for example a syringe) having a longitudinal axis parallel (and/or nearly parallel for example between 1 to 10 degrees and/or 10 to 30 degrees) to a skin contact surface or a base of the injector during drug delivery. Optionally, the long axis of the skin contact surface and/or base of a patch injector may be longer than the height of the injector perpendicular to the skin contact surface. In some embodiments, a skin contact surface of a patch injector and/or stabilized pen injector may include a connector for connecting to an injection site.
For example, a connector may include an adhesive. For example, a stabilized pen injector may include a drug reservoir (for example a syringe) having a longitudinal axis perpendicular (and/or at a large angle for example between 90 to 80 degrees and/or 80 to 60 degrees and/or between 60 degrees to 30 degrees) to a skin contact surface or a base. Optionally, the long axis of the skin contact surface and/or base of a stabilized pen injector may be shorter than the height of the injector perpendicular to the skin contact surface.
In some embodiments, needle insertion and/or retraction and/or protection may be automatic. For example, movement of a needle and/or a needle shield (e.g. insertion and/or retraction and/or deployment of a shield and/or withdrawal of the shield) may be powered by an actuator (for example a piston and/or a magnet) and/or a stored energy source (for example a spring and/or a battery). Alternatively or additionally, movement of a needle and/or a needle shield (e.g. insertion and/or retraction and/or deployment of a shield and/or withdrawal of the shield) may be manually powered, for example by pushing an injector and/or a button towards an injection site and/or by pulling the injector away from the site.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Flow Chart of an Exemplary Method of Needle Protection
Optionally the needle is protected before a skin contact surface of the device is removed from the site. For example, the needle may be protected from temporary exposure while the device is being removed. For example, the device may include a base attached to the subject and a body. A needle retraction mechanism may include interlocked parts connected to body and the base. Pulling the body away from the subject may extend the body away from the base and/or disengage the interlocked parts of the retraction mechanism. For example, disengaging the interlocked parts may unlock the needle and/or trigger retraction of the needle.
In some embodiments, an injection device may have an active state 112 wherein a skin contact surface of the device is connected to a needle insertion site, for example on the skin a subject. In the active state 112, a needle is optionally extended into the subject. Optionally, a locking mechanism maintains the needle in the extended position. Alternatively or additionally, the device may include a needle protection mechanism. The locking mechanism and/or needle protection mechanism optionally includes at least one part that moves with the base interlocked to at least one part that moves with the body.
In some embodiments, a user will move 114 the body of the device, for example in order to remove the device from an injection site. Optionally, the user may start removing the device by an intuitive movement. For example, removal may be by pulling the body away from the skin. Optionally, while the body is moved by the user, the skin contact surface remains attached 115 Moving 114 the body optionally causes relative movement 116 between the base and the body.
In some embodiments, the user is encouraged to pull the body from a specific location on the body and/or in a specific direction. For example the housing may have some surfaces that are difficult to pull (for example then are convex and/or face away from the surface and/or low friction) and/or other surfaces that are configured to easily be pulled (for example including indentations for gripping and/or a high friction coating and/or angled toward the skin contact surface). Optionally, there may be markings instructing the user to pull here and/or remove from here etc.
In some embodiments, the body and base of the injector may be free to move relative to each other and/or biased to move relative to each other. Alternatively or additionally, relative movement between the body of the injector and the skin contact surface may be inhibited by a retaining mechanism. For example, the body may be attached to the same surface as the base and/or the body and base may be biased toward one another.
Optionally, the when causing relative movement between the base and the body of the injector, the user may overcome the retaining mechanism. For example, the user may detach the body from the injection site while the base remains attached to the injection site. Alternatively or additionally, at certain times, relative movement may be inhibited (for example during drug delivery) and at other times, relative movement may be facilitated.
For example, at the end of injection the retaining mechanism may be automatically nullified. For example, nullifying the retaining mechanism may facilitate relative movement. Alternatively or additionally, the body of the injector may move on its own respective to the base (e.g. pop up away from the injections site). Optionally, when the retaining mechanism is nullified, the device may remain attached (e.g. by the base) to the injections site.
In some embodiments, relative movement 116 between the base and the body may further cause relative movement between 117 interlocked parts in the needle protection mechanism. The relative movement 117 of parts of the protection mechanism may initiate 118 protection of the needle tip. For example, relative movement 117 may unlock a needle (e.g. allowing it to retract) and/or unlock of a needle shield (e.g. allowing it to extend to cover the needle). For example, relative movement 117 may trigger movement of a needle (e.g. triggering retraction of the needle point) and/or trigger movement of a needle shield (e.g. extending it to cover the needle). For example, initiating 118 and/or initiating protection may include by retracting the needle and/or shielding the needle.
In some embodiments, the device may be removed 120 from the user after the needle is protected. For example, the skin contact surface may be pulled and/or peeled from the injection zone.
Flow Chart of an Exemplary Method of Initiating a Drug Delivery Device
Optionally initiated the device may include extending a needle in accordance with an embodiment of the present invention. Optionally, a user prepares a patch injector for use by simple intuitive steps. Optionally, multiple steps may be performed simultaneously with one act and/or sequentially and/or with multiple acts. Optionally, the a step in preparing the device will cue the user toward the next step, which may include a logical continuation of the preparing. The initiation of the device may be intuitive and/or robust against failure even when misused and/or avoid exposing of a user to hazards under various conditions (proper use, misuse and/or failure).
In some embodiments, the device may be packaged in a way that presents the device in a proper orientation for further preparation of the device. For example, when the packaging is open, the device may be presented to the user in a way that encourages gripping of the device in the proper way for further initiation steps. For example, a griping surface and/or a surface opposite the skin contact surface of the device may be presented to the user upon opening the packaging.
In some embodiments, the packaging may expose a user interface in an early part of unpacking the device. For example, the user interface may be viewable through a window in the packaging before the package is fully opened. Alternatively or additionally, the packaging may be designed such that when the package is opened the user interface faces the user.
Alternatively or additionally, the device may be placed in the packaging such that when the device is unpacked 101 (for example, when it is removed from the packaging) the user interface is exposed to the user. Optionally, the user interface may include familiar operational features. For example, features may include a manually operated feature (for example a pull tab, a pull ring, and/or a button) and/or a display (for example a screen and/or a light and/or a window). The position of the feature may encourage the user to hold the device with the feature operable and/or with the display visible (for example directing his gripping of the device not to cover up a feature and/or orienting the device such that the feature faces the user's limbs and/or eyes).
In some embodiments, a user may prepare 102 a device for use. For example, preparing a device for use may include removing a sterile needle cap and/or removing a protective liner from a skin contact surface. Optionally, multiple components of the device may be interconnected and/or prepared together. For example, a protective needle cap and an adhesive liner may be connected to a single handle, for example a pull ring. Pulling the pull ring optionally removes the cap and the liner together.
Alternatively or additionally, preparing 102 one part may start a process that enables and/or causes preparing 102 of another part.
In some embodiments, a drug delivery device may be attached to a subject. For example, the device may include a skin contact surface that is attached 103 to the skin of the subject. Optionally, attachment 103 is by means of an adhesive. Optionally, the device and/or packaging thereof may be designed to encourage the user to properly attach the device. For example, the skin contact surface may be larger and/or flatter than another surface of the device that does not contact the skin. In some embodiments, the presence of adhesive on the contact surface of the device will serve as an intuitive clue to the user that this surface should be attached to the skin. Optionally, a surface of the device that is not to be attached to the subject may include a feature that intuitively should be exposed, for example an operation feature of the device (e.g. a display and/or a control interface).
In some embodiments, a drug delivery device may include a safety feature to prevent drug delivery before certain steps are performed. For example, in some embodiments, a skin contact surface may serve as a skin sensor. The device may be designed to inhibit extension of a needle and/or discharge of a drug unless the skin contact surface is in contact and/or attached to the subject. For example, an activation button of a drug delivery device may be locked until a skin sensor registers placement of the device on an injection site. For example, the skin sensor may include a skin contact surface. Optionally, when the device has been prepared for use, an activation button may be locked. The button is optionally unlocked 106 by collapsing 104 the skin contact surface into device (for example placing the contact surface onto the injection site and pushing the body of the device towards the skin).
In some embodiments, a drug delivery device may insert a needle through the skin of a subject and/or discharge a drug to the subject. For example, once an activation button is unlocked, pushing the button may cause needle insertion 110 and/or drug delivery 111. In some embodiments, needle insertion is automatic, for example, pressing an activation button may trigger 108 a spring based needle insertion. Alternatively or additionally, force of the user pushing on the activation button may manually extend the needle into the injection site. Alternatively or additionally, the needle may be inserted when the sensor senses contact with the injection site. For example, the user may push the device onto the injection site, collapsing a base of the injector inward, exposing the needle. Alternatively or addition, a sensor may trigger a needle extension mechanism when it senses contact with the injection site.
State Diagram of an Injector
In some embodiments, an injection device may have an active state 212. For example active state 212 may include a working state (e.g. while the device is delivering a drug to a user) and/or a waiting state (e.g. while the device is waiting before delivering a drug and between multiple drug deliveries events and/or after completing delivery).
Optionally, in active state 212 an attachment surface of the device is attached to an injection site and/or supports the device on an injection site. Optionally, in active state 212, a delivery channel, for example a needle and/or a cannula, protrudes into the user at the injection site. For example, the delivery channel may protrude into the user through an opening in the skin contact surface.
In some embodiments, in active state 212, the base of the device may be engaged to the body of the device (for example the body of the device may include a housing of the device and/or a needle driver). For example, the base may be interlocked to the needle driver to lock the needle in an extended position. For example, a part that is attached to the base and/or moves with base may interlock to a part that is attached to the body of the device and/or moves with the body of the device. Alternatively or additionally, in the working state 212 the base may be retained engaged to the body. For example, engagement between the body and the base may expose a needle tip (for example the base may collapse against the body of the device to expose the needle protruding through an opening in the base). Optionally, the base and body may be retained in the engaged state by mutual connection to an external object (for example a surface, for example an area around an injection site). Alternatively or additionally, the base and body may be retained together by a locking mechanism.
In some embodiments, before removing a delivery device from a user, the device may be switched to a disengaged state 216. For example, switching the device a disengaged state may include disengaging the base from the body of the injector.
Optionally the body is disengaged from the base while the base remains attached to the injection site.
In some embodiments, a user action may switch the device from the active to the disengaged state. For example, the user may the pull the body of the device away from the base of the device to disengage the base from the body. Optionally, the user may overcome a retaining mechanism to disengage the base from the body of the device. Alternatively or additionally, under certain conditions, the base may automatically be disengaged from the body of the device. For example, upon completion of drug delivery the body of the device may automatically be disengaged from the base.
In some embodiments, the disengagement is partial. For example, the base may be disengaged from the body by distancing the body from the base while the base still supports the body and/or connects the body to the injections site.
In some embodiments, disengaging a base of the device from a body of the device may trigger and/or facilitate protection of a delivery channel. For example, in the active state a needle may be locked with a needle point in an extended position. The locking mechanism may include engaged parts connected to the body and/or base of the device. Disengaging the base from the body optionally rearranges the engaged parts and/or unlocks the needle allowing the needle to be retracted and/or facilitating retraction of the needle.
In some embodiments, disengaging the base from the body of the device causes the device to switch to a protected state 218. For example, a movement between the base and the body of the device may cause retraction of a needle tip through an opening of the base of the device into a protected position. Alternatively or additionally, relative movement between the base and the body of the device may cause extension of the base to a position shielding the needle. In the protected state 218, the base optionally remains attached to the injection site. Alternatively or additionally, in protected state 218 the base may support the body on the injection site.
In some embodiments, in protected state 218, the device may be removed 220 from the injections site. Optionally, in protected state 218 the needle may be retracted making it easier to separate the device from the injection site. For example, the base may be peeled from the injection site without moving the needle inside the skin of the user and/or without exposing the user to a sharp stick hazard.
Patch Injector
In some embodiments, base 302 may include a contact surface configured to attach to an injection site 320. For example, the contact surface may include an adhesive configured to adhere to skin of injection site 320. Optionally, the adhesive on the base is strong enough to support the weight of the entire device. For example, the adhesive may hold the device from falling when the weight is pulling the device away from the injection site and/or the adhesive may prevent sheering movement of the device when the weight is directed parallel to the injection surface. For example, the adhesive on the base may have a surface area between 1 cm2 to 5 cm2 and/or between 5 cm2 to 15 cm2 and/or between 15 cm2 to 80 cm2 or more. Optionally, the adhesive on the base will have a flexible skirt. For example, the skirt may have a length of between 1 mm to 5 mm or between 5 mm to 20 mm or more.
In some embodiments, a body 304 of the device may be connected to the base. For example, the body of the device may include a housing and/or a chassis and/or an energy source and/or a drug reservoir and/or an actuator and/or a pump for discharging the drug through a delivery channel and/or through the injection site into a subject.
Optionally, body 304 and base 302 are connected for relative movement. For example, while base 302 remains attached to injection site 320, body 304 may move relative to the injection site. Optionally, body 304 and base 302 may be connected via a hinge and/or a sliding joint.
In some embodiments, a needle driver 318 may drive insertion and/or retraction of a deliver channel, for example including a needle 310. For example, needle driver 318 may include an elastic element driving movement of needle 310 with respect to the contact surface of base 302. For example, driver 318 may drive extension a sharp tip of needle 310 through an opening in base 302 into the injection site and/or driver 318 may retract the tip of needle 310 through the opening in base 302 back from the injection site. Optionally, driver 318 is mounted to base 302. Alternatively or additionally, driver 318 may be mounted to body 304.
In some embodiments, needle driver 310 is controlled by a locking/triggering mechanism 308. For example, mechanism 308 may trigger retraction and/or extension of needle 310. Optionally mechanism 308 may respond to changes in the relative positions of body 304 and base 302 to trigger retraction and/or extension. For example, when needle 310 is extended, mechanism 308 may retract needle 310 in response to a movement of body 304 away from base 302. For example, when needle 310 is locked in an extended position, mechanism 308 may unlock needle 310 in response to a movement of body 304 away from base 302. In some embodiments, a mechanical linkage may interconnect 306 mechanism 308, base 302 and/or body 304. For example, relative movements of the components may cause physical locking/unlocking and/or trigger insertion/retraction. Alternatively or additionally, mechanism 308 may include an electronic sensor, an electrical switch and/or a logic processor and/or an optical sensor sensitive to relative movements of base 302 and body 304.
In some embodiments, the system may be biased towards retraction and/or extension of needle 310. For example, base 302 may be biased toward body 304 and/or away from the body. Optionally a retaining mechanism may hold body 304 and/or base 302 in a fixed configuration. Optionally a user action will overcome biasing and/or a retention mechanism to extend and/or retract and/or lock and/or unlock needle 310.
For example, in some embodiments, base 302 may be biased away from body 304. Optionally, in an active state, base 302 and body 304 are both attached to an injection site. When a user pulls body 304 away from the injection site, base 302 stays on the site and/or is distanced from base 302. Optionally, distancing base 302 from body 304 triggers needle retraction.
In some embodiments, a discharge mechanism and/or a user interface and/or a logical controller are sensitive to the relative positions of base 302 and body 304. For example, an activation button for discharge may be blocked when base 302 is distanced from body 304. Alternatively or additionally, a logic unit may register and/or communicate an error condition when base 302 moves with respect to body 304 in a way that is not according to the specified order of operation of the device. Optionally the error may lead to locking and/or stopping and/or disabling of certain systems of the device. For example, premature distancing of base 302 from body 304 during drug discharge may cause an error condition and/or cause a stopping of drug delivery. For example, the base may move with respect to the body between 0.1 mm to 1.0 mm and/or between 1 mm to 2 mm and/or between 2 mm to 4 mm and/or between 4 mm to 10 mm and/or between 10 mm to 30 mm. For example, the distance moved may be measured where the maximum relative movement occurs.
In some embodiments, an injector may be supplied with in a locked state. For example, the user may prepare the device by unpacking it, opening the device (for example releasing a base of the device to an extended state). For example, preparing the device may include removing a protective cap and/or removing a protective covering. For example, an adhesive protector may be removed from a skin contact surface on the base of the injector and/or on the body of the injector. Optionally, during unpacking and/or preparing the device, the device may be connected to a power source and/or a computing device (for example a personal computing device of the user). For example, a set of live instructions may be displayed. Optionally preparing the device places the device into a skin detection state. For example, removing the needle cap and/or adhesive protector may extend a base and/or a skin sensor. For example, removing the needle cap and/or adhesive protector may unlock the base and/or the skin sensor for example allowing them to collapse toward the body of the device when attached to an injection site.
In some embodiments, in the skin detection state, base 402 of the device may be extended away from body of the device. For example, a rear portion of base 402 is pivoted away from chassis 404. Optionally, base 404 includes a skin contact surface 407 on a bottom surface thereof. A vector normal 409 to skin contact surface 407 optionally points away from the body of the device. For example, traveling from surface 407 in the direction of normal 409 may move away from a center of gravity of the body.
Alternatively or additionally traveling from surface 407 in the direction of normal 409 may move away from a nearest point on the body.
In some embodiments, base 402 of the injector may be attached to the skin of a subject (for example at an injection zone) while the device is in the skin detection state.
Optionally after attachment, the chassis 404 is moved towards the base and/or the skin to facilitate activation of the device. For example, facilitating activation of the device may include triggering needle insertion. Alternatively or additionally, facilitating activation of the device may include unlocking an activation switch and/or a needle insertion trigger. Alternatively and/or additionally, attaching the base 402 and moving chassis 404 towards the injection site may be a continuous process. For example, as the user pushes the prepared device onto the skin, first, the contact surface of the base 402 of the device contacts the skin and/or then the chassis 404 is pushed toward the base and/or the skin.
In some embodiments, in the skin detection state, prior to activation, the skin contact surface of the injector may be biased away (for example outward) from the body of the injector. For example, base 402 is biased away from chassis 404. Base 404 is optionally collapsed towards chassis 404 by overcoming the outward biasing force.
Optionally, a retaining force is supplied to retain base 402 in the collapsed state. For example, chassis 404 may include a contact surface 413 and/or an adhesive that retains base 402 in the collapsed state. Optionally, after base 402 is attached to the injection site and/or base 402 collapses into chassis 404, surface 413 contacts and/or attaches to the skin. Attachment of surface 413 to the skin optionally holds base 402 collapsed together with chassis 404. Alternatively or additionally, base 402 may be biased toward chassis 404. Alternatively or additionally, biasing and/or a retaining force may change based on a state of the injector. For example, when drug delivery is completed
In some embodiments, the attachment mechanism of the injector may be interlocked to a needle driver and/or a needle extension mechanism. For example, needle 410 is rigidly mounted to an extension 424 of a cartridge. Cartridge 422 is optionally rigidly mounted to a plate 411, which is connected to and/or moves with respect to chassis 404. For example, plate 411 is configured to rotate around a pivot 448. For example, pivot 448 may be fixed in relation to chassis 404 and/or mounting plate 411 may rotate around a location on chassis 404. Movement of plate 411 around pivot 448 optionally causes needle 410 to move longitudinally (for example in an arc trajectory) from a protected position (for example inside the body as illustrated in
In some embodiments, in the skin detection state, a needle 410 of the injector is substantially perpendicular to contact surface 407 of base 402 (for example needle may range between 0 to 2 degrees and/or 2 to 5 degrees and/or 5 to 10 degrees and/or 10 to 20 degrees and/or 20 to 45 degrees from parallel to normal 409). For example, the orientation of needle 410 to surface 407 may facilitate preparation of the device for example including removal of a needle cap and/or adhesive protector.
Some embodiments may include a plunger driver. For example, a plunger driver may include a telescoping screw assembly 426 and/or a motor and/or a battery and/or a transmission. Alternatively or additionally, a plunger driver may include an expanding gas and/or linear actuator and/or a piston.
Optionally, base 402 is interconnected to a lock that keeps needle 410 in the retracted position. For example, collapsing base 402 toward the body may unlock the needle 410 and/or a needle driver. For example, plate 411 may rotate around a pivot 448 to extend needle 410. For example, collapsing base 402 may unlock an activation switch of the injector. Activating the injector optionally triggers a needle driver, to drive needle point 428 into the extended position and/or into the skin of a subject.
In some embodiments, needle tip 428 is inserted into a subject by a rotating needle driver. For example, the needle drive drives plate 411 to rotate around joint 448.
Optionally, in the active state, a longitudinal axis of a barrel of cartridge 422 is substantially parallel to skin contact surface 407 and/or base 402. For example, hinge 448 and hinge 449 are at opposite sides of the injector and/or rotate in the same direction. Alternatively or additionally, two hinges may be on the same side of the device and rotate in opposite directions. Rotation of one hinge may compensate for movement of another hinge such that the relationship between the injector cartridge and the base during the active stage is similar to the relation between the cartridge and the base in the skin detection state (for example before placing the device onto the skin of the user).
For example, in the skin detection state and/or in the active state the base 402 may be parallel to the longitudinal axis of the cartridge 422. For example, in the skin detection state and/or in the active state the base 402 may be perpendicular to the longitudinal axis of needle 410. In some embodiments, in the active state, a needle 410 of the injector is substantially perpendicular to contact surface 407 of base 402 (for example needle may range between 0 to 2 degrees and/or 2 to 5 degrees and/or 5 to 10 degrees and/or 10 to 20 degrees and/or 20 to 45 degrees from parallel to normal 409). For example, the orientation of needle 410 to surface 407 in the active state may be the same or similar to the orientation of needle 410 to surface 407 in the skin detection state. For example the difference in the angle between 410 to surface 407 in the active state to the skin detection state may be range between 0 to 3 degrees and/or between 3 to 10 degrees and/or between 10 to 30 degrees. In some embodiments, base 402 may remain in a collapsed state until the user pulls the body away from the skin. Optionally, an additional skin contact surface may be brought into contact with the skin of the user when the base collapses. For example, an additional contact surface 413 may be on the body of the injector. For example, surface 413 may have an adhesive. Optionally, adhesion of surface 413 to the skin of the subject may inhibit movement of the body away from the skin and/or keep base 402 in the collapsed state.
Alternatively or additionally, there may be a locking mechanism that holds base 402 collapsed during the primed and/or active states of the device.
Alternatively or additionally, the bias of base 402 with respect to the body may depend on the position of base 402 with respect to the body and/or may be depend on the state of the injector.
In some embodiments, a lock may not be released until a threshold force is applied to the body of the device and/or until a section of the body of the device (for example contact surface 413) moves in relation to base 402. For example, contact surface 413 may be biased outward, inward and/or backward and/or interconnected with a lock so that base 402 is released when surface 413 is moved with relation to base 402 and/or the injection zone. Optionally a lock may be released at the end of discharge of a drug and/or upon malfunction of the injector making it easier to trigger needle release. Optionally, releasing the lock may require a pulling the body away from the skin with a particular direction, force, and/or over a minimal time period. For example, unlocking base 402 only for a particular combination of force and/or direction and/or time may avoid base 402 being released unintentionally (for example do to momentum caused by movements of the subject.
Optionally, after needle retraction, needle 410 may be inhibited from being reexposed. For example, the needle exposure process described above with respect to
Optionally, base 402 is biased away from the body. Biasing optionally extends base 402 away from the body whenever there is no force preventing extension. For example, base 402 may extend away from the body when surface 413 is separated from the skin regardless of whether the body is pulled away from base 402 or the separation is due to other factors (for example peeling the adhesive from the skin). Alternatively or additionally, base 402 may be biased toward the body. For example, extension of base 402 may be due to adhesive forces pulling contact surface 407 towards the injection site as the body is pulled away from the injection site.
Optionally the base includes a skin contact surface. For example, the skin contact surface may include an adhesive. For example, the adhesive may be configured to adhere the contact surface to the skin of a subject, for example near and/or surrounding a needle insertion site. The injector is optionally configured to encourage intuitive placement and/or removal of the device and/or intuitive triggering of needle insertion and/or retraction.
In some embodiments, features on the injector encourage intuitive understanding of placement of the injector on the skin. For example, one or more skin contact surfaces 507, 505 of the injector may include an adhesive 540. Adhesive 540 may be covered with an adhesive protector liner 534. Preparing the injector for use optionally includes peeling one or more adhesive liners 534 off of adhesive 540. Peeling adhesive liners 534 from adhesive 540 clues the user to the need to place and/or stick surfaces 507 and 505 to the skin. Optionally, in the skin detecting state contact surfaces 505 and 507 may not form a continuous surface. For example, there may be a gap. For example, the gap may range between 0.1 and 0.3 cm and/or between 0.3 and 0.6 cm and/or between 0.6 to 1.2 cm and/or between 1.2 to 2.4 cm and/or greater than 2.4 cm.
A user may intuitively understand that he should place the protruding contact surface 507 against the skin and then push against the body to collapse gap 515 and bring contact surface 505 into contact with the skin. In some embodiments a single adhesive liner 534 covers multiple adhesive areas (for example contact surfaces 507 and/or 505). Alternatively or additional, separate adhesive areas may be covered by separate adhesive liners. In some embodiments, a single handle 532 is used to prepare multiple aspects of the injector (for example to remove adhesive liners from contact surfaces 505 and/or 507 and/or to remove the needle cover). Alternatively or additional, separate handles may be used to prepare separate aspects of the injector.
In some embodiments, an injector includes an adhesive covering a skin contact surface. For example, an adhesive 540 may cover a first skin contact surface 507 on base 502. A separate section of adhesive optionally covers a second skin contact surface 505 on the body (for example on a rear portion of chassis 504). Optionally the adhesive may overhang beyond the edge of base 502 and/or chassis 504. For example, an adhesive skirt may overhang beyond the front and sides of base 502. Optionally the overhang is strengthened by a stiffener 536a, 536b.
In some embodiments, a handle is included for intuitive preparation of the injector. For example, a pull ring handle 532 is connected to a needle cover and/or adhesive liner 534. Handle 532 optionally supplies an intuitive clue to a user that he should remove the needle cover and/or adhesive liner 534 before placing contact surface 507 against the skin. Optionally, the injector includes a lock preventing priming of the injector until handle 532 has been moved (for example until handle 532 has been pulled away from the injector along with the needle cap and/or adhesive liner 534). For example, a skin sensor may be covered and/or locked in a disengaged state (for example extended away from the body) and/or example an activation switch (for example a button 542) may be locked in an inactivated position until handle 534 is pulled away from the injector. In some embodiments, different preparation activities are connected such that a user can perform one action and prepare multiple parts of the injector. For example, the needle cover may connect to an adhesive liner 534 that covers both skin contact surface 507 on base 502 and skin contact surface 505 on housing 530.
Optionally peeling off adhesive liner 534 from both contact surfaces 505 and 507 and removing the needle cover (for example by pulling the needle cover through an opening 503 in base 502) are achieved with one intuitive act of pulling pull ring 532 away from base 502. Alternatively or additionally, a separate adhesive protector may be supplied for each contact surface 505, 507 and/or removing the needle cover may be independent of removing an adhesive protector.
In some embodiments, features on the body facilitate intuitive placement of the injector. For example, the base that is placed on the skin may be the largest flat surface of the injector. Optionally, the top of the injector (opposite the skin contact surface may include a user interface (for example a switch for example button 542 and/or a display for example window 531). A user may intuitively understand that a display and/or button will not be attached against the skin. Optionally sides of the injector that are not placed against the skin will be generally non-flat (e.g. rounded and/or include protrusions and/or indentations).
In some embodiments, opening 503 in base 502 of the device may be large enough to insert and/or remove a sterile needle cover. For example, the width of the opening may range between 1 mm to 2 mm and/or between 2 mm to 4 mm and/or between 4 mm to 10 mm.
Optionally, surface 605b includes an adhesive for attaching to the skin of a subject. For example, when the device is active, adhesion between surface 605b and the skin of the subject may retain the body on the skin and/or retain a base 602 of the injector in a collapsed position next to chassis 604b.
In some embodiments, when surface 605a or 605b is pulled away from the skin of the user, base 602 may move away from chassis 604a or 604b, causing needle retraction.
In some embodiments, base 602 includes a skin contact surface and/or an adhesive. For example, the adhesive on base 602 may be strong enough to support the injector on an injection site. Optionally, base 602 includes a needle opening 603. For example, when the injector is in an active state, a needle may protrude through opening 603 into an injection site. Optionally, opening 603 is large enough to insert and/or remove a needle cover from a needle when the needle is retracted behind base 603 for example as illustrated in
In some embodiments base 602 is attached to housing 630a, 630b and/or chassis 604a, 604b via a hinge. For example, the hinge may be near needle hole 603 (e.g. nearer to the front end of the device with the needle hole than the rear end of the device opposite the needle hole). For example, movement of the needle hole may be less than movement of the opposite end of base 602 when base 602 is moved away from chassis 604a, 604b. For example, the location of the center of mass of the needle hole may range between 0 to 10% of the distance between the hinge and the far end of the base and/or between 10 to 30% of the distance between the hinge and the far end of the base and/or between 30 to 50% of the distance between the hinge and the far end of the base and/or between 50 to 80% of the distance between the hinge and the far end of the base and/or
In some embodiments, needle retraction occurs when the skin contact surface 505 of the chassis 504 and/or on a body of the pharmaceutical delivery device lifts off a skin 693 of a subject. Alternately or additionally, in some embodiments the needle retracts while a skin contact surface 505 of the chassis and/or body of the injector is still connected to the skin. For example, the relative movement between the skin contact surfaces of the based 502 and the skin contact surface of the chassis 505 that triggers needle retraction may be more than and/or less than the distance that the skin can stretch to compensate for such movements. For example, the distance of relative movement between the skin contact surface on the base and the skin contact surface on the chassis and/or body of the injector at their closest points may range between 0 to 0.3 mm and/or between 0.3 to 1 mm and/or between 1 mm to 3 mm and/or between 3 mm to 10 mm and/or between 10 mm to 30 mm. Alternatively or additionally, the base may pivot with respect to the body and/or chassis of the injector to an angle of between 0 to 2 degrees and/or between 2 to 6 degrees and/or between 6 to 12 degrees and/or between 12 to 24 degrees and/or between 24 to 45 degrees when the needle retracts.
For example, in an embodiment in an embodiment where contact surface 505 remains in contact with the skin while the needle retracts, needle retraction may occur when base 502 pivots outward less than 3 degrees and/or less than 5 degrees and/or less than 10 degrees. For example, in an embodiment in an embodiment where contact surface 505 remains in contact with the skin while the needle retracts, needle retraction may occur when the closes points between base 502 and contact surface 505 move between 0 to 0.3 mm and/or between 0.3 to 1 mm and/or between 1 mm to 3 mm and/or between 3 mm to 5 mm relative to one another.
Optionally wheel 752 rotates around an axis 548.
In some embodiments, a stored energy source impels drive wheel 752. For example, a stored energy source may include a spiral torsion spring 762.
In some embodiments, in the ready state, base 502 may interfere with pushing an activation button 542. For example, while base 502 is extended away from the chassis 504 of the injector, interference element 756 may block movement of an extension 760 of button 542. Optionally, opening 503 is near the pivot 449 of base 502 and/or opening 503 is aligned with needle 410 while base 502 is in the extended position. For example, alignment of needle 410 and opening 503 may allow a needle cover to extend through opening 503.
Optionally base 502 includes a biasing member. For example, member includes an elastic element that is deformed when base 502 is collapsed into chassis 504 and/or forces base 502 into the extended position. For example, member includes a leaf spring that is pushed up against a front wall of chassis 504 when base 502 is collapsed. Alternatively or alternatively, a biasing member may include a coil spring and/or a torsion spring and/or a cushioning element.
Optionally, in the primed state, pin 748 holds track 746 and/or mounting plate 411 and/or needle tip 428 in a retracted position behind the skin contact surface.
Alternatively or additionally, movement of base 502 may directly cause element 758 to move out of the way of spur 754 of wheel 752. For example, of needle tip 428 may extend immediately upon collapse of base 402 toward chassis 404 without the user pushing a button. Alternatively or additionally, needle tip 428 may be extended manually, for example, by a force of the user pushing housing 530 and/or a button 542 towards the injection site, for example, needle extension may not be powered by a stored energy source in the injector.
In some embodiments, in the primed state, opening 503 is aligned with needle 410 such that movement of mounting plate 411 towards chassis 504 and/or base 502 extends needle tip 428 out opening 503.
In some embodiments, base 502 is biased outwards, away from chassis 504. For example, even if somehow base 502 is peeled off the injection site without opening, biasing will cause base 502 to open and/or retract needle tip 428. Alternatively or additionally, a base may rotate freely without biasing and/or the base may be biased inward (toward the chassis). For example, when the body is pulled away from the injection site, the adhesive may pull the base away from the body and/or cause needle retraction. Alternatively or additionally, the needle may not retract with respect to the body. For example, when the base extends away from the body it may extend outward past the needle tip and/or shield the needle tip, for example to prevent a stick hazard.
Adhesive Structure
Optionally the needle cap and liner 534 may removed and peeled off together.
Alternatively or additionally, an adhesive structure may have a different number of parts and/or layers.
Stabilized Injector
In some embodiments, base 902 is retained in a collapsed state, for example, base 902 may be biased towards housing 930. Alternatively, a retaining and/or locking mechanism retains base 902 in the collapsed state. Optionally, an actuator delivers a drug through needle 910 into the subject while the adhesive retains the device on an injection site and/or while the device is retained in the active state.
In some embodiments, a user may pull housing 930 away from an injection site (for example at the end of drug delivery and/or before the end of drug delivery). For example, pulling housing 930 away from an injection site while base 902 remains adhered to the injection site overcomes a retaining mechanism and/or deploys a shield, for example by extending base 902 to a protecting state.
In alternative embodiments, a stabilized pen injector optionally includes a needle insertion and/or retraction mechanism. For example, the insertion and/or retraction may perform insertion and/or retraction via an actuator and/or a stored energy source that is triggered for example by extending and/or collapsing base 910.
Alternative Patch Needle Mechanism
Optionally, before placement of the device, pin 1049 is prevented from moving to the right by a vertical portion of the wall of track 1052. Needle 1010 is optionally retracted upward and/or base 1002 is optionally extended downward.
Exemplary Dimensions of a Drug Delivery Device
In some embodiments the payload of a reservoir (for example a syringe) may include, for example between 0.5 and 2 ml and/or between 2 and 7 ml and/or between 7 and 6 ml and/or between 7 and 10 ml of a drug and/or more. In some embodiments, the injector may discharge the entire payload as a single dose. A drug delivery device may include, for example, a patch injector, and/or an internally powered driver to drive the plunger and/or discharge the payload.
For the sake of this application, an internally powered injector driver may be defined as a drive mechanism powered by energy stored at least temporarily within the injector. Power may be stored in a power supply, for instance as chemical potential (for example a chemical that produces an expanding gas and/or a battery) and/or mechanical potential (for example stored in an elastic member and/or a spring and/or a pressurized gas). For example, the driver may be designed to discharge the payload over a time period ranging between 20 and 120 seconds and/or between 120 and 600 seconds and/or between 600 seconds and an hour and/or between an hour and a day and/or longer.
In some embodiments, the apparatus may be preprogrammed to wait a fixed time delay ranging between 2 to 20 minutes and/or 20 minutes to an hour and/or an hour to 6 hours and/or 6 hours to 2 days after activation before beginning delivery of the substance. Optionally the length of the time delay may be an estimated time for a temperature sensitive component of the apparatus to reach a preferred working temperature. For example, the temperature sensitive component may include the drug and/or a battery.
In general, discharge may be driven by a driver. An internally powered driver may be powered by various mechanisms including for example a motor as discussed, including for example a DC motor, an actuator, a brushless motor, and/or a transmission including for example a telescoping assembly and/or a threaded element and/or a gear and/or a coupling and/or an elastic mechanism (for example a spring and/or a rubber band) and/or an expanding gas and/or a hydraulic actuator).
A drug delivery device in accordance with some embodiments of the present invention may include a reservoir part as discussed. For example, a reservoir may include a medicine container and/or a syringe. Optionally a syringe may be preloaded with medicine using standard equipment and/or in an aseptic room. A preloaded syringe may optionally include a proximal opening. A plunger may optionally seal the proximal opening and/or protect the sterility of the contents of the syringe. A sterile needle, typically hollow, may optionally be connected to the syringe barrel. For example, the hollow of the needle may be in fluid communication with the interior of the barrel.
The needle may optionally be rigidly attached to the extension at the distal end of the barrel. The sterility of all and/or part of the needle may for example be protected by a protective cap. The protective cap may remain on the needle when the syringe is supplied and/or installed into an injector. For example, the medicine container may optionally include a cylindrical barrel rigidly attached to a needle. In some embodiments, a plunger may slide axially along the inside of the barrel to discharge a medicine payload. For example, the medicine may be discharged through the hollow needle. The protruding tip of the needle may be oriented at an angle to the axis of the barrel.
An aspect ratio of the base may be defined as the ratio of the length of the longest axis of the base to the shortest axis. Optionally the axis ratio may range between 1 to 1.5 and/or 1.5 to 2 and/or between 2 to 3 and/or greater than 3. In some embodiments, the height of the injector may range between half the length of the short axis of the base to the length of the short axis of the base and/or between the length of the short axis of the base to twice the length of the short axis of the base and/or greater than the twice length of the short axis of the base. The height of the injector may supply leverage for pivoting the adhesive off the skin of a patient after use.
In some embodiments, the force to insert the needle to the skin of a patient may range for example between 0.02 to 0.2 N and/or between 0.2 and 0.5 N and/or between 0.5 to 5 N. Optionally, the force required to inject the drug (for example the force on a syringe plunger) may range for example between 5 to 60 N. For example, the force required to inject the drug may depend on the injection rate and/or the viscosity of the drug and/or the syringe geometry and/or the needle dimensions.
In some embodiments, a needle protection mechanism may be triggered by a linear force greater than, for example, between 10 to 60 N.
For example, drug delivery device may include an auto-injector. The auto-injector may be activated by manually pushing with enough force to insert the needle. The device may then apply an injection force to inject a drug. Once the entire drug is injected and/or when there is an obstruction and/or occlusion, the injection force may rise until it passes a threshold triggering safeguarding of the needle and/or ending injection.
For example in the event of an occlusion and/or at the end of delivery, the linear force generated by the device may increase to the level of up to 60 N. A needle safeguarding mechanism (for example a needle retraction mechanism) may be sensitive to the force. For example, the mechanism may include a snap that gives way at 70 N returning the needle to the retracted position.
In some embodiments, the stress to inject a medicine and/or to trigger safeguarding of a needle may include a torque. For example, injection of medicine may be driven by a plunger. The plunger may optionally be driven by a threaded assembly, for example a threaded screw and/or teeth and/or a telescoping assembly. Optionally the pitch of the teeth and/or an associated screw may range for example between 0.5 and 2 mm. The diameter of the screw may range for example between 2.5 and 15 mm. The torque to power injection may range for example between 0.2 and 1.0 N*cm. The trigger torque (the torque at which the needle safeguarding is triggered) may range for example between to 0.5 to 2 and/or from 2 to 7 and/or from 7 to 10N*cm.
During injection, the linear movement of a plunger may range for example between 10-50 mm. The length of movement of the plunger may vary for example with the volume of medicine to be injected that may range for example between 0.5 to 3 ml.
In some embodiments, a safeguarding mechanism may be sensitive to a torque. For example, the needle may be retracted when the mechanism is exposed to a twisting moment. Optionally, discharge may be driven by a torque. For example, the driver may apply torque to threaded element pushing a plunger. When the torque on the driver reaches a threshold value, the needle may be released and/or retracted and/or a needle shield may be deployed. Alternatively or additionally, the trigger mechanism may require both a torque and a linear force. For example, requiring both a torque and a linear stress may prevent premature activation due to momentary friction.
In some embodiments a time of discharge may range may depend on the fill volume and/or viscosity For example the expected injection speeds may be Injection speed depend on viscosity, for example for viscosity ranging from 1 cp to 15 cp the expected injection rage may range between 30 to 70 sec/1 ml, for example for viscosity ranging from 15 cp to 60 cp the expected injection rate may range between 35 to 60 sec/ml for viscosity above 60 cp the expected injection rate may range between 53 to 67 sec/1 ml. The maximum and/or minimum expected injection time may for example be the maximum and/or minimum allowed fill volume divided by an injection rate.
For example an expected time of discharge may range for example between 24 to 78 seconds (for example for between 0.8 and 1.2 ml of fluid having a viscosity ranging between 1 to 15 cp) and/or between 36 to 68 seconds (for example for between 1.2 and 1.7 ml of fluid having a viscosity ranging between 1 to 15 cp) and/or between 51 to 92 seconds (for example for between 1.7 and 2.3 ml of fluid having a viscosity between 1 to 15 cp) and/or between 70 to 150 seconds (for example for 2.0 to 2.5 ml of fluid having a viscosity of between 15 and 70 cp) and/or between 120 seconds and 3 minutes for larger volumes and/or viscosities. In some embodiments, injection times may be longer. The length of the injection time may be determined by considerations other than viscosity and/or volume.
In some embodiments, the reservoir may have a length ranging for example between 20 and 72 and/or 72 and 78 mm and/or 78 and 80 mm and/or 80 and 200 mm. In some embodiments an internal cylindrical space of a reservoir may have an average width ranging for example between 1 and 3 mm and/or 3 and 10 and/or 10 and 15 mm and/or 15 and 25 mm and/or 25 and 50 mm. Optionally a reservoir may have a circular cross section such that width is the diameter of the circle. In some embodiments, an extension may have a straight end portion with a length ranging for example between 1 and 3 mm or 3 and 7 mm or 7 and 8 or 8 and 10 mm or 10 and 15 mm or 15 and 50 mm. In some embodiments, the exposed straight portion of a needle may have a length ranging for example between 1 and 5 mm or 5 and 7 mm or 7 and 10 mm or 10 and 20 mm.
In some embodiments, an extension may have a sealing ring for a needle cap. The sealing ring may have a length ranging for example between 0.1 and 0.6 mm or 0.6 and 1 mm or 1 and 2.5 mm or 2.5 and 3 mm or 3 and 6 mm or 6 and 15 mm. In some embodiments a sealing ring may have an internal cavity with a length ranging for example between 0.5 and 1.5 mm/or 1.5 and 2.5 mm or 2.5 and 5 mm or 5 and 10 mm.
In some embodiments the sealing ring may have an external average width which may also be an average outer diameter ranging for example between 1 and 7 mm or 7 and 5 mm or 5 and 10 mm or 10 and 20 mm. In some embodiments the sealing ring may have an internal average width which also may be an average inner diameter ranging for example between 1 and 3 mm or 3 and 7 mm or 7 and 10 mm or 10 and 18 mm. In some embodiments, the extension may have a neck (not including the sealing ring) with an average width which may be an average diameter ranging for example between 1 and 3 mm or 3 and 7 mm or 7 and 8 mm or 8 and 16 mm. Optionally the neck may have a non-uniform cross section (for example an I beam and/or cross shaped cross section) and/or a tapered cross section.
For a non-uniform cross section, an average outer width may be defined as the width of the smallest oval that can enclose the neck averaged over the length of the neck. In some embodiments a fluid path between the extension and a reservoir cavity may include a 27 gauge needle or a needle ranging between 25 and 30 gauge or a needle ranging between 20 and 25 gauge or a needle ranging between 30 and 32 gauge. In some embodiments a needle protruding from an extension may include a 27 gauge needle or a needle ranging between 25 and 30 gauge or a needle ranging between 20 and 25 gauge or a needle ranging between 30 and 32 gauge.
It is expected that during the life of a patent maturing from this application many relevant technologies and/or materials will be developed and the scope of the terms are intended to include all such new technologies and materials a priori.
As used herein the terms “about”, “approximately” and “substantially” refer to ±5%.
The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
The term “consisting of” means “including and limited to”.
The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 7, from 1 to 5, from 2 to 7, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 7, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
This application claims the benefit of co-pending U.S. patent application Ser. No. 16/071,538, titled “Needle Insertion and Retraction Mechanism”, filed Jul. 20, 2018, which is a section 371 of International Application No. PCT/US16/68367, filed Dec. 22, 2016, which was published in the English language on Jul. 27, 2017 under International Publication No. WO 2017/127215 A1, which claims priority to International Application No. PCT/US16/56223, filed Oct. 10, 2016, International Application No. PCT/US16/56238, filed Oct. 10, 2016, International Application No. PCT/US16/56247, filed on Oct. 10, 2016, all of which claim the benefit of U.S. Provisional Application No. 62/281,536, filed Jan. 21, 2016, the disclosures of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 232432 | Allison | Sep 1880 | A |
| 1125887 | Schimmel | Jan 1915 | A |
| 1321550 | Platt | Nov 1919 | A |
| 1704921 | Nicoll | Mar 1929 | A |
| 1795530 | Cowan et al. | Mar 1931 | A |
| 1795630 | Wilson | Mar 1931 | A |
| 2453590 | Poux | Nov 1948 | A |
| 2589426 | Ogle | Mar 1952 | A |
| 2677373 | George | May 1954 | A |
| 2702547 | Glass | Feb 1955 | A |
| 2860635 | Wilburn | Nov 1958 | A |
| 3203269 | Perrine | Aug 1965 | A |
| 3212685 | James et al. | Oct 1965 | A |
| 3585439 | Schneeberger | Jun 1971 | A |
| 3623474 | Heilman et al. | Nov 1971 | A |
| 3705582 | Stumpf et al. | Dec 1972 | A |
| 3708945 | Klettke | Jan 1973 | A |
| 3794028 | Mueller et al. | Feb 1974 | A |
| 3834387 | Brown | Sep 1974 | A |
| 3994295 | Wulff | Nov 1976 | A |
| 4085747 | Lee | Apr 1978 | A |
| 4189065 | Herold | Feb 1980 | A |
| 4195636 | Behnke | Apr 1980 | A |
| 4218724 | Kaufman | Aug 1980 | A |
| 4254768 | Ty | Mar 1981 | A |
| 4273122 | Whitney et al. | Jun 1981 | A |
| 4300554 | Hessberg et al. | Nov 1981 | A |
| 4324262 | Hall | Apr 1982 | A |
| 4403987 | Gottinger | Sep 1983 | A |
| 4425120 | Sampson et al. | Jan 1984 | A |
| 4435173 | Siposs et al. | Mar 1984 | A |
| 4465478 | Sabelman et al. | Aug 1984 | A |
| 4502488 | Degironimo et al. | Mar 1985 | A |
| 4504263 | Steuer et al. | Mar 1985 | A |
| 4549554 | Markham | Oct 1985 | A |
| 4564054 | Gustavsson | Jan 1986 | A |
| 4565543 | Bekkering et al. | Jan 1986 | A |
| 4583974 | Kokernak | Apr 1986 | A |
| 4585439 | Michel | Apr 1986 | A |
| 4599082 | Grimard | Jul 1986 | A |
| 4601702 | Hudson | Jul 1986 | A |
| 4636201 | Ambrose et al. | Jan 1987 | A |
| 4664654 | Strauss | May 1987 | A |
| 4685903 | Cable et al. | Aug 1987 | A |
| 4695274 | Fox | Sep 1987 | A |
| 4698055 | Sealfon | Oct 1987 | A |
| 4702738 | Spencer | Oct 1987 | A |
| 4704105 | Adorjan et al. | Nov 1987 | A |
| 4710178 | Henri et al. | Dec 1987 | A |
| 4729208 | Galy et al. | Mar 1988 | A |
| 4735311 | Lowe et al. | Apr 1988 | A |
| 4737144 | Choksi | Apr 1988 | A |
| 4772272 | McFarland | Sep 1988 | A |
| 4810215 | Kaneko | Mar 1989 | A |
| 4810249 | Haber et al. | Mar 1989 | A |
| 4813426 | Haber et al. | Mar 1989 | A |
| 4840185 | Hernandez | Jun 1989 | A |
| 4850966 | Grau et al. | Jul 1989 | A |
| 4861341 | Woodburn | Aug 1989 | A |
| 4863434 | Bayless | Sep 1989 | A |
| 4867743 | Vaillancourt | Sep 1989 | A |
| 4874383 | Mcnaughton | Oct 1989 | A |
| 4882575 | Kawahara | Nov 1989 | A |
| 4886499 | Cirelli et al. | Dec 1989 | A |
| 4892521 | Laico et al. | Jan 1990 | A |
| 4897083 | Martell | Jan 1990 | A |
| 4900310 | Ogle, II | Feb 1990 | A |
| 4915702 | Haber | Apr 1990 | A |
| 4919569 | Wittenzellner | Apr 1990 | A |
| 4919596 | Slate et al. | Apr 1990 | A |
| 4923446 | Page et al. | May 1990 | A |
| 4929241 | Kulli | May 1990 | A |
| 4950241 | Ranford | Aug 1990 | A |
| 4950246 | Muller | Aug 1990 | A |
| 4957490 | Byrne et al. | Sep 1990 | A |
| 4964866 | Szwarc | Oct 1990 | A |
| 4994045 | Ranford | Feb 1991 | A |
| 4998924 | Ranford | Mar 1991 | A |
| 5019051 | Hake | May 1991 | A |
| 5051109 | Simon | Sep 1991 | A |
| 5062828 | Waltz | Nov 1991 | A |
| D322671 | Szwarc | Dec 1991 | S |
| 5088988 | Talonn et al. | Feb 1992 | A |
| 5109850 | Blanco et al. | May 1992 | A |
| 5112317 | Michel | May 1992 | A |
| 5114406 | Gabriel et al. | May 1992 | A |
| 5127910 | Talonn et al. | Jul 1992 | A |
| 5131816 | Brown et al. | Jul 1992 | A |
| 5147326 | Talonn et al. | Sep 1992 | A |
| 5156599 | Ranford et al. | Oct 1992 | A |
| 5190521 | Hubbard et al. | Mar 1993 | A |
| 5217437 | Talonn et al. | Jun 1993 | A |
| 5246670 | Haber et al. | Sep 1993 | A |
| 5254096 | Rondelet et al. | Oct 1993 | A |
| 5267977 | Feeney, Jr. | Dec 1993 | A |
| 5269762 | Armbruster et al. | Dec 1993 | A |
| 5275582 | Wimmer | Jan 1994 | A |
| 5282593 | Fast | Feb 1994 | A |
| 5295966 | Stern et al. | Mar 1994 | A |
| 5298023 | Haber et al. | Mar 1994 | A |
| 5300045 | Plassche, Jr. | Apr 1994 | A |
| 5318522 | D'Antonio | Jun 1994 | A |
| 5338311 | Mahurkar | Aug 1994 | A |
| 5342313 | Campbell et al. | Aug 1994 | A |
| 5348544 | Sweeney et al. | Sep 1994 | A |
| 5366498 | Brannan et al. | Nov 1994 | A |
| 5376785 | Chin et al. | Dec 1994 | A |
| 5383865 | Michel | Jan 1995 | A |
| D356150 | Duggan et al. | Mar 1995 | S |
| 5415645 | Friend et al. | May 1995 | A |
| 5456360 | Griffin | Oct 1995 | A |
| 5478315 | Brothers et al. | Dec 1995 | A |
| 5478316 | Bitdinger et al. | Dec 1995 | A |
| 5482446 | Williamson et al. | Jan 1996 | A |
| 5496274 | Graves et al. | Mar 1996 | A |
| 5501665 | Jhuboo et al. | Mar 1996 | A |
| 5505709 | Funderburk et al. | Apr 1996 | A |
| 5562624 | Righi et al. | Oct 1996 | A |
| 5562686 | Sauer et al. | Oct 1996 | A |
| 5593390 | Castellano et al. | Jan 1997 | A |
| 5609580 | Kwiatkowski et al. | Mar 1997 | A |
| 5611785 | Mito et al. | Mar 1997 | A |
| 5616132 | Newman | Apr 1997 | A |
| 5624400 | Firth et al. | Apr 1997 | A |
| 5637095 | Nason et al. | Jun 1997 | A |
| 5643218 | Lynn et al. | Jul 1997 | A |
| 5645530 | Boukhny et al. | Jul 1997 | A |
| 5645955 | Maglica | Jul 1997 | A |
| 5647853 | Feldmann et al. | Jul 1997 | A |
| 5658256 | Shields | Aug 1997 | A |
| 5662678 | Macklin | Sep 1997 | A |
| 5672160 | Osterlind et al. | Sep 1997 | A |
| 5690618 | Smith et al. | Nov 1997 | A |
| 5697908 | Imbert et al. | Dec 1997 | A |
| 5697916 | Schraga | Dec 1997 | A |
| 5725500 | Micheler | Mar 1998 | A |
| 5728075 | Levander | Mar 1998 | A |
| D393314 | Meisner et al. | Apr 1998 | S |
| 5741275 | Wyssmann | Apr 1998 | A |
| 5766186 | Faraz et al. | Jun 1998 | A |
| 5776103 | Kriesel et al. | Jul 1998 | A |
| 5795675 | Maglica | Aug 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5810167 | Fujii | Sep 1998 | A |
| 5810784 | Tamaro | Sep 1998 | A |
| 5814020 | Gross | Sep 1998 | A |
| 5830187 | Kriesel et al. | Nov 1998 | A |
| 5836920 | Robertson | Nov 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851197 | Marano et al. | Dec 1998 | A |
| 5858001 | Tsals et al. | Jan 1999 | A |
| 5858008 | Capaccio | Jan 1999 | A |
| 5868710 | Battiato et al. | Feb 1999 | A |
| 5893842 | Imbert | Apr 1999 | A |
| 5894015 | Rechtin | Apr 1999 | A |
| 5919167 | Mulhauser et al. | Jul 1999 | A |
| 5926596 | Edwards et al. | Jul 1999 | A |
| 5931814 | Alex et al. | Aug 1999 | A |
| 5941850 | Shah et al. | Aug 1999 | A |
| 5944699 | Barrelle et al. | Aug 1999 | A |
| 5948392 | Haslwanter et al. | Sep 1999 | A |
| 5954697 | Srisathapat et al. | Sep 1999 | A |
| 5957895 | Sage et al. | Sep 1999 | A |
| 5968011 | Larsen et al. | Oct 1999 | A |
| 5989221 | Hjertman | Nov 1999 | A |
| 5993423 | Choi | Nov 1999 | A |
| 6004296 | Jansen et al. | Dec 1999 | A |
| 6004297 | Steenfeldt-Jensen et al. | Dec 1999 | A |
| 6033245 | Yamkovoy | Mar 2000 | A |
| 6033377 | Rasmussen et al. | Mar 2000 | A |
| 6045533 | Kriesel et al. | Apr 2000 | A |
| 6064797 | Crittendon et al. | May 2000 | A |
| 6074369 | Sage et al. | Jun 2000 | A |
| 6162197 | Mohammad | Dec 2000 | A |
| 6186979 | Dysarz | Feb 2001 | B1 |
| 6186982 | Gross et al. | Feb 2001 | B1 |
| 6189292 | Odell et al. | Feb 2001 | B1 |
| 6200289 | Hochman et al. | Mar 2001 | B1 |
| 6200296 | Dibiasi et al. | Mar 2001 | B1 |
| 6224569 | Brimhall | May 2001 | B1 |
| 6248093 | Moberg | Jun 2001 | B1 |
| 6270481 | Mason et al. | Aug 2001 | B1 |
| 6277095 | Kriesel et al. | Aug 2001 | B1 |
| 6277098 | Klitmose et al. | Aug 2001 | B1 |
| 6277099 | Strowe et al. | Aug 2001 | B1 |
| 6287283 | Ljunggreen et al. | Sep 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6302633 | Poe | Oct 2001 | B1 |
| 6336729 | Pavelle et al. | Jan 2002 | B1 |
| 6345968 | Shupe | Feb 2002 | B1 |
| 6362591 | Moberg | Mar 2002 | B1 |
| 6377848 | Garde et al. | Apr 2002 | B1 |
| 6391005 | Lum et al. | May 2002 | B1 |
| 6423029 | Elsberry | Jul 2002 | B1 |
| D461243 | Niedospial | Aug 2002 | S |
| D465026 | May et al. | Oct 2002 | S |
| 6458102 | Mann et al. | Oct 2002 | B1 |
| 6485461 | Mason et al. | Nov 2002 | B1 |
| 6485465 | Moberg et al. | Nov 2002 | B2 |
| 6500150 | Gross et al. | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6511336 | Turek et al. | Jan 2003 | B1 |
| 6517517 | Farrugia et al. | Feb 2003 | B1 |
| D471274 | Diaz et al. | Mar 2003 | S |
| D471983 | Hippolyte et al. | Mar 2003 | S |
| 6554800 | Nezhadian et al. | Apr 2003 | B1 |
| 6555986 | Moberg | Apr 2003 | B2 |
| 6558351 | Steil et al. | May 2003 | B1 |
| 6565541 | Sharp | May 2003 | B2 |
| 6585695 | Adair et al. | Jul 2003 | B1 |
| 6589229 | Connelly et al. | Jul 2003 | B1 |
| 6595956 | Gross et al. | Jul 2003 | B1 |
| 6595960 | West et al. | Jul 2003 | B2 |
| 6645181 | Lavi et al. | Nov 2003 | B1 |
| 6652482 | Hochman | Nov 2003 | B2 |
| 6656158 | Mahoney et al. | Dec 2003 | B2 |
| 6656159 | Flaherty | Dec 2003 | B2 |
| 6659980 | Moberg et al. | Dec 2003 | B2 |
| 6673033 | Sciulli et al. | Jan 2004 | B1 |
| 6679862 | Diaz et al. | Jan 2004 | B2 |
| 6685678 | Evans et al. | Feb 2004 | B2 |
| 6689118 | Alchas et al. | Feb 2004 | B2 |
| 6699218 | Flaherty et al. | Mar 2004 | B2 |
| 6719141 | Heinz et al. | Apr 2004 | B2 |
| 6722916 | Buccinna et al. | Apr 2004 | B2 |
| 6743211 | Prausnitz et al. | Jun 2004 | B1 |
| 6749587 | Flaherty | Jun 2004 | B2 |
| 6752783 | Hung et al. | Jun 2004 | B2 |
| 6752787 | Causey et al. | Jun 2004 | B1 |
| 6767336 | Kaplan | Jul 2004 | B1 |
| 6768425 | Flaherty et al. | Jul 2004 | B2 |
| 6786890 | Preuthun et al. | Sep 2004 | B2 |
| 6800071 | Mcconnell et al. | Oct 2004 | B1 |
| 6805687 | Dextradeur et al. | Oct 2004 | B2 |
| 6817990 | Yap et al. | Nov 2004 | B2 |
| 6824529 | Gross et al. | Nov 2004 | B2 |
| 6843782 | Gross et al. | Jan 2005 | B2 |
| 6854620 | Ramey | Feb 2005 | B2 |
| 6905298 | Haring | Jun 2005 | B1 |
| 6907679 | Yarborough et al. | Jun 2005 | B2 |
| 6908452 | Diaz et al. | Jun 2005 | B2 |
| 6960192 | Flaherty et al. | Nov 2005 | B1 |
| 6979316 | Rubin et al. | Dec 2005 | B1 |
| 6997727 | Legrady et al. | Feb 2006 | B1 |
| 7001360 | Veasey et al. | Feb 2006 | B2 |
| 7004104 | Kundus | Feb 2006 | B1 |
| 7004929 | Mcwethy et al. | Feb 2006 | B2 |
| 7025226 | Ramey | Apr 2006 | B2 |
| 7033338 | Vilks et al. | Apr 2006 | B2 |
| 7034223 | Fan et al. | Apr 2006 | B2 |
| 7048715 | Diaz et al. | May 2006 | B2 |
| 7060054 | Nissels | Jun 2006 | B2 |
| 7060059 | Keith et al. | Jun 2006 | B2 |
| 7063684 | Moberg | Jun 2006 | B2 |
| 7066909 | Peter et al. | Jun 2006 | B1 |
| 7094221 | Veasey et al. | Aug 2006 | B2 |
| 7097637 | Triplett et al. | Aug 2006 | B2 |
| 7112187 | Karlsson | Sep 2006 | B2 |
| 7128727 | Flaherty et al. | Oct 2006 | B2 |
| 7144384 | Gorman et al. | Dec 2006 | B2 |
| 7193521 | Moberg et al. | Mar 2007 | B2 |
| D544092 | Lewis | Jun 2007 | S |
| 7225694 | Said | Jun 2007 | B2 |
| 7247149 | Beyerlein | Jul 2007 | B2 |
| 7250037 | Shermer et al. | Jul 2007 | B2 |
| 7267669 | Staunton et al. | Sep 2007 | B2 |
| RE39923 | Blom | Nov 2007 | E |
| 7291132 | Deruntz et al. | Nov 2007 | B2 |
| 7291159 | Schmelzeisen-Redeker et al. | Nov 2007 | B2 |
| 7303549 | Flaherty et al. | Dec 2007 | B2 |
| 7306578 | Gray et al. | Dec 2007 | B2 |
| 7326194 | Zinger et al. | Feb 2008 | B2 |
| 7344385 | Chen | Mar 2008 | B2 |
| 7364570 | Gerondale et al. | Apr 2008 | B2 |
| 7377912 | Graf et al. | May 2008 | B2 |
| 7390312 | Barrelle | Jun 2008 | B2 |
| 7390314 | Stutz et al. | Jun 2008 | B2 |
| 7407493 | Cane | Aug 2008 | B2 |
| 7418880 | Smith | Sep 2008 | B1 |
| D578210 | Muta et al. | Oct 2008 | S |
| 7442186 | Blomquist | Oct 2008 | B2 |
| 7455663 | Bikovsky | Nov 2008 | B2 |
| 7465290 | Reilly | Dec 2008 | B2 |
| 7468055 | Prais et al. | Dec 2008 | B2 |
| 7488181 | Van | Feb 2009 | B2 |
| 7497842 | Diaz et al. | Mar 2009 | B2 |
| 7500963 | Westbye et al. | Mar 2009 | B2 |
| 7501587 | English | Mar 2009 | B2 |
| 7503786 | Kato et al. | Mar 2009 | B2 |
| 7530964 | Lavi et al. | May 2009 | B2 |
| 7540858 | Dibiasi | Jun 2009 | B2 |
| 7547281 | Hayes et al. | Jun 2009 | B2 |
| 7565208 | Harris et al. | Jul 2009 | B2 |
| 7569050 | Moberg et al. | Aug 2009 | B2 |
| D600341 | Loerwald | Sep 2009 | S |
| 7585287 | Bresina et al. | Sep 2009 | B2 |
| 7588559 | Aravena et al. | Sep 2009 | B2 |
| 7589974 | Grady et al. | Sep 2009 | B2 |
| D602155 | Foley et al. | Oct 2009 | S |
| D602586 | Foley et al. | Oct 2009 | S |
| 7597682 | Moberg | Oct 2009 | B2 |
| D604835 | Conley | Nov 2009 | S |
| 7611491 | Pickhard | Nov 2009 | B2 |
| 7621893 | Moberg et al. | Nov 2009 | B2 |
| 7628770 | Ethelfeld | Dec 2009 | B2 |
| 7628772 | Mcconnell et al. | Dec 2009 | B2 |
| 7628782 | Mair et al. | Dec 2009 | B2 |
| 7637891 | Wall | Dec 2009 | B2 |
| 7637899 | Woolston et al. | Dec 2009 | B2 |
| 7641649 | Moberg et al. | Jan 2010 | B2 |
| 7658734 | Adair et al. | Feb 2010 | B2 |
| 7660627 | Mcnichols et al. | Feb 2010 | B2 |
| 7678079 | Shermer et al. | Mar 2010 | B2 |
| 7682338 | Griffin | Mar 2010 | B2 |
| 7686787 | Moberg et al. | Mar 2010 | B2 |
| 7699829 | Harris et al. | Apr 2010 | B2 |
| 7699833 | Moberg et al. | Apr 2010 | B2 |
| 7704088 | Sakamoto | Apr 2010 | B2 |
| 7704227 | Moberg et al. | Apr 2010 | B2 |
| 7704229 | Moberg et al. | Apr 2010 | B2 |
| 7704231 | Pongpairochana et al. | Apr 2010 | B2 |
| 7708717 | Estes et al. | May 2010 | B2 |
| 7713238 | Mernoe | May 2010 | B2 |
| 7713240 | Istoc et al. | May 2010 | B2 |
| 7717903 | Estes et al. | May 2010 | B2 |
| 7717913 | Novak et al. | May 2010 | B2 |
| 7722574 | Toman et al. | May 2010 | B2 |
| 7736333 | Gillespie, III | Jun 2010 | B2 |
| 7736344 | Moberg et al. | Jun 2010 | B2 |
| 7744589 | Mounce et al. | Jun 2010 | B2 |
| 7749194 | Edwards et al. | Jul 2010 | B2 |
| 7758548 | Gillespie et al. | Jul 2010 | B2 |
| 7758550 | Bollenbach et al. | Jul 2010 | B2 |
| 7766867 | Lynch et al. | Aug 2010 | B2 |
| 7766873 | Moberg et al. | Aug 2010 | B2 |
| 7776030 | Estes et al. | Aug 2010 | B2 |
| 7780637 | Jerde et al. | Aug 2010 | B2 |
| 7789857 | Moberg et al. | Sep 2010 | B2 |
| 7794426 | Briones et al. | Sep 2010 | B2 |
| 7794427 | Estes et al. | Sep 2010 | B2 |
| 7801599 | Young et al. | Sep 2010 | B2 |
| 7806868 | De et al. | Oct 2010 | B2 |
| 7828528 | Estes et al. | Nov 2010 | B2 |
| 7837659 | Bush et al. | Nov 2010 | B2 |
| 7846132 | Gravesen et al. | Dec 2010 | B2 |
| 7854723 | Hwang et al. | Dec 2010 | B2 |
| 7857131 | Vedrine | Dec 2010 | B2 |
| 7879025 | Jacobson et al. | Feb 2011 | B2 |
| 7892206 | Moberg et al. | Feb 2011 | B2 |
| 7901382 | Daily et al. | Mar 2011 | B2 |
| 7905867 | Veasey et al. | Mar 2011 | B2 |
| 7918825 | O'Connor et al. | Apr 2011 | B2 |
| 7935104 | Yodfat et al. | May 2011 | B2 |
| 7935105 | Miller et al. | May 2011 | B2 |
| 7938803 | Mernoe et al. | May 2011 | B2 |
| 7955305 | Moberg et al. | Jun 2011 | B2 |
| 7967784 | Pongpairochana et al. | Jun 2011 | B2 |
| 7967795 | Cabiri | Jun 2011 | B1 |
| 7976514 | Abry et al. | Jul 2011 | B2 |
| 7981105 | Adair et al. | Jul 2011 | B2 |
| 7988683 | Adair et al. | Aug 2011 | B2 |
| 7993300 | Nyholm et al. | Aug 2011 | B2 |
| 7993301 | Boyd et al. | Aug 2011 | B2 |
| 7998111 | Moberg et al. | Aug 2011 | B2 |
| 7998131 | Adair et al. | Aug 2011 | B2 |
| 8002754 | Kawamura et al. | Aug 2011 | B2 |
| 8021357 | Tanaka et al. | Sep 2011 | B2 |
| 8025658 | Chong et al. | Sep 2011 | B2 |
| 8029469 | Ethelfeld | Oct 2011 | B2 |
| 8034019 | Nair et al. | Oct 2011 | B2 |
| 8034026 | Grant et al. | Oct 2011 | B2 |
| 8038666 | Triplett et al. | Oct 2011 | B2 |
| 8057431 | Woehr et al. | Nov 2011 | B2 |
| 8057436 | Causey et al. | Nov 2011 | B2 |
| 8062253 | Nielsen et al. | Nov 2011 | B2 |
| 8062255 | Brunnberg et al. | Nov 2011 | B2 |
| 8062257 | Moberg et al. | Nov 2011 | B2 |
| 8065096 | Moberg et al. | Nov 2011 | B2 |
| 8066694 | Wagener | Nov 2011 | B2 |
| D650079 | Presta et al. | Dec 2011 | S |
| D650903 | Kosinski et al. | Dec 2011 | S |
| 8086306 | Katzman et al. | Dec 2011 | B2 |
| D652503 | Cameron et al. | Jan 2012 | S |
| 8105279 | Mernoe et al. | Jan 2012 | B2 |
| 8105293 | Pickhard | Jan 2012 | B2 |
| 8114046 | Covino et al. | Feb 2012 | B2 |
| 8114064 | Alferness et al. | Feb 2012 | B2 |
| 8114066 | Naef et al. | Feb 2012 | B2 |
| 8118781 | Knopper et al. | Feb 2012 | B2 |
| 8121603 | Zhi | Feb 2012 | B2 |
| D657462 | Siroky | Apr 2012 | S |
| 8147446 | Yodfat et al. | Apr 2012 | B2 |
| 8151169 | Bieth et al. | Apr 2012 | B2 |
| 8152764 | Istoc et al. | Apr 2012 | B2 |
| 8152770 | Reid | Apr 2012 | B2 |
| 8152779 | Cabiri | Apr 2012 | B2 |
| 8152793 | Keinaenen et al. | Apr 2012 | B2 |
| 8157693 | Waksmundzki | Apr 2012 | B2 |
| 8157769 | Cabiri | Apr 2012 | B2 |
| 8162674 | Cho et al. | Apr 2012 | B2 |
| 8162923 | Adams et al. | Apr 2012 | B2 |
| 8167841 | Teisen-Simony et al. | May 2012 | B2 |
| 8172591 | Wertz | May 2012 | B2 |
| 8172804 | Bikovsky | May 2012 | B2 |
| 8177749 | Slate et al. | May 2012 | B2 |
| 8182447 | Moberg et al. | May 2012 | B2 |
| 8182462 | Istoc et al. | May 2012 | B2 |
| 8197444 | Bazargan et al. | Jun 2012 | B1 |
| 8206351 | Sugimoto et al. | Jun 2012 | B2 |
| 8221356 | Enggaard et al. | Jul 2012 | B2 |
| 8257345 | Adair et al. | Sep 2012 | B2 |
| 8267893 | Moberg et al. | Sep 2012 | B2 |
| 8267921 | Yodfat et al. | Sep 2012 | B2 |
| 8273061 | McConnell et al. | Sep 2012 | B2 |
| 8287520 | Drew et al. | Oct 2012 | B2 |
| 8292647 | Mcgrath et al. | Oct 2012 | B1 |
| 8303572 | Adair et al. | Nov 2012 | B2 |
| 8308679 | Hanson et al. | Nov 2012 | B2 |
| 8308695 | Laiosa | Nov 2012 | B2 |
| 8323250 | Chong et al. | Dec 2012 | B2 |
| 8348898 | Cabiri | Jan 2013 | B2 |
| 8366668 | Maritan | Feb 2013 | B2 |
| 8372039 | Mernoe et al. | Feb 2013 | B2 |
| 8373421 | Lindegger et al. | Feb 2013 | B2 |
| 8409141 | Johansen et al. | Apr 2013 | B2 |
| 8409142 | Causey et al. | Apr 2013 | B2 |
| 8409143 | Lanigan et al. | Apr 2013 | B2 |
| 8409149 | Hommann et al. | Apr 2013 | B2 |
| 8414533 | Alexandersson | Apr 2013 | B2 |
| 8414557 | Istoc et al. | Apr 2013 | B2 |
| 8425468 | Weston | Apr 2013 | B2 |
| 8430847 | Mernoe et al. | Apr 2013 | B2 |
| 8465455 | Cabiri | Jun 2013 | B2 |
| 8469942 | Kow et al. | Jun 2013 | B2 |
| 8474332 | Bente et al. | Jul 2013 | B2 |
| 8475408 | Mernoe et al. | Jul 2013 | B2 |
| 8479595 | Vazquez et al. | Jul 2013 | B2 |
| 8483980 | Moberg et al. | Jul 2013 | B2 |
| 8490790 | Cocheteux et al. | Jul 2013 | B2 |
| 8495918 | Bazargan et al. | Jul 2013 | B2 |
| 8496862 | Zelkovich et al. | Jul 2013 | B2 |
| 8500716 | Adair et al. | Aug 2013 | B2 |
| 8512287 | Cindrich et al. | Aug 2013 | B2 |
| 8512295 | Evans et al. | Aug 2013 | B2 |
| 8517987 | Istoc et al. | Aug 2013 | B2 |
| 8517992 | Jones | Aug 2013 | B2 |
| 8523803 | Favreau | Sep 2013 | B1 |
| 8551046 | Causey et al. | Oct 2013 | B2 |
| 8556856 | Bazargan et al. | Oct 2013 | B2 |
| 8562364 | Lin et al. | Oct 2013 | B2 |
| 8568361 | Yodfat et al. | Oct 2013 | B2 |
| 8574216 | Istoc et al. | Nov 2013 | B2 |
| 8603026 | Favreau | Dec 2013 | B2 |
| 8603027 | Favreau | Dec 2013 | B2 |
| 8603028 | Mudd et al. | Dec 2013 | B2 |
| 8617110 | Moberg et al. | Dec 2013 | B2 |
| 8622966 | Causey et al. | Jan 2014 | B2 |
| 8628510 | Bazargan et al. | Jan 2014 | B2 |
| 8632499 | Grant et al. | Jan 2014 | B2 |
| 8647074 | Moberg et al. | Feb 2014 | B2 |
| 8647296 | Moberg et al. | Feb 2014 | B2 |
| 8647303 | Cowe | Feb 2014 | B2 |
| 8668672 | Moberg et al. | Mar 2014 | B2 |
| 8674288 | Hanson et al. | Mar 2014 | B2 |
| 8679060 | Mernoe et al. | Mar 2014 | B2 |
| 8681010 | Moberg et al. | Mar 2014 | B2 |
| D702834 | Norton et al. | Apr 2014 | S |
| 8690855 | Alderete et al. | Apr 2014 | B2 |
| 8708961 | Field et al. | Apr 2014 | B2 |
| 8715237 | Moberg et al. | May 2014 | B2 |
| 8721603 | Lundquist | May 2014 | B2 |
| 8751237 | Kubota | Jun 2014 | B2 |
| 8753326 | Chong et al. | Jun 2014 | B2 |
| 8753331 | Murphy | Jun 2014 | B2 |
| 8764707 | Moberg et al. | Jul 2014 | B2 |
| 8764723 | Chong et al. | Jul 2014 | B2 |
| 8771222 | Kanderian et al. | Jul 2014 | B2 |
| 8777896 | Starkweather et al. | Jul 2014 | B2 |
| 8777924 | Kanderian et al. | Jul 2014 | B2 |
| 8777925 | Patton | Jul 2014 | B2 |
| 8784369 | Starkweather et al. | Jul 2014 | B2 |
| 8784370 | Lebel et al. | Jul 2014 | B2 |
| 8784378 | Weinandy | Jul 2014 | B2 |
| 8790295 | Sigg et al. | Jul 2014 | B1 |
| 8795224 | Starkweather et al. | Aug 2014 | B2 |
| 8795231 | Chong et al. | Aug 2014 | B2 |
| 8795260 | Drew | Aug 2014 | B2 |
| 8801668 | Ali et al. | Aug 2014 | B2 |
| 8801679 | Iio et al. | Aug 2014 | B2 |
| 8810394 | Kalpin | Aug 2014 | B2 |
| 8814379 | Griffiths et al. | Aug 2014 | B2 |
| 8845587 | Lanigan et al. | Sep 2014 | B2 |
| 8858508 | Lavi et al. | Oct 2014 | B2 |
| 8864739 | Moberg et al. | Oct 2014 | B2 |
| 8876770 | Kraft et al. | Nov 2014 | B2 |
| 8876778 | Carrel | Nov 2014 | B2 |
| 8911410 | Ekman et al. | Dec 2014 | B2 |
| 8915882 | Cabiri | Dec 2014 | B2 |
| 8915886 | Cowe | Dec 2014 | B2 |
| 8920374 | Bokelman et al. | Dec 2014 | B2 |
| 8932266 | Wozencroft | Jan 2015 | B2 |
| 8979802 | Woehr | Mar 2015 | B2 |
| 8986250 | Beebe et al. | Mar 2015 | B2 |
| 9011164 | Filman et al. | Apr 2015 | B2 |
| 9011371 | Moberg et al. | Apr 2015 | B2 |
| 9011387 | Ekman et al. | Apr 2015 | B2 |
| 9033925 | Moberg et al. | May 2015 | B2 |
| 9061104 | Daniel | Jun 2015 | B2 |
| 9061110 | Avery et al. | Jun 2015 | B2 |
| 9072827 | Cabiri | Jul 2015 | B2 |
| 9072845 | Hiles | Jul 2015 | B2 |
| 9089475 | Fangrow | Jul 2015 | B2 |
| 9089641 | Kavazov | Jul 2015 | B2 |
| 9107999 | Moberg et al. | Aug 2015 | B2 |
| 9138534 | Yodfat et al. | Sep 2015 | B2 |
| 9149575 | Cabiri | Oct 2015 | B2 |
| 9173996 | Gray et al. | Nov 2015 | B2 |
| 9173997 | Gross et al. | Nov 2015 | B2 |
| 9180248 | Moberg et al. | Nov 2015 | B2 |
| 9205188 | Lanigan et al. | Dec 2015 | B2 |
| 9205199 | Kemp et al. | Dec 2015 | B2 |
| D747799 | Norton et al. | Jan 2016 | S |
| 9233215 | Hourmand et al. | Jan 2016 | B2 |
| 9259532 | Cabiri | Feb 2016 | B2 |
| 9283327 | Hourmand et al. | Mar 2016 | B2 |
| 9308318 | Lanigan et al. | Apr 2016 | B2 |
| 9308327 | Marshall et al. | Apr 2016 | B2 |
| 9314569 | Causey et al. | Apr 2016 | B2 |
| 9320849 | Smith et al. | Apr 2016 | B2 |
| 9327073 | Moberg et al. | May 2016 | B2 |
| 9339607 | Langley et al. | May 2016 | B2 |
| 9345834 | Henley et al. | May 2016 | B2 |
| 9345836 | Cabiri et al. | May 2016 | B2 |
| 9350634 | Fadell | May 2016 | B2 |
| 9352090 | Brereton et al. | May 2016 | B2 |
| 9364606 | Cindrich et al. | Jun 2016 | B2 |
| 9364608 | Moberg et al. | Jun 2016 | B2 |
| 9381300 | Smith et al. | Jul 2016 | B2 |
| 9393365 | Cabiri | Jul 2016 | B2 |
| 9421323 | Cabiri et al. | Aug 2016 | B2 |
| 9421337 | Kemp et al. | Aug 2016 | B2 |
| 9427531 | Hourmand et al. | Aug 2016 | B2 |
| 9433732 | Moberg et al. | Sep 2016 | B2 |
| 9433733 | Moberg et al. | Sep 2016 | B2 |
| 9446188 | Grant et al. | Sep 2016 | B2 |
| 9446196 | Hourmand et al. | Sep 2016 | B2 |
| 9452261 | Alon | Sep 2016 | B2 |
| 9463280 | Cabiri | Oct 2016 | B2 |
| 9463889 | Schmitz et al. | Oct 2016 | B2 |
| 9468720 | Mudd et al. | Oct 2016 | B2 |
| 9474859 | Ekman et al. | Oct 2016 | B2 |
| 9492622 | Brereton et al. | Nov 2016 | B2 |
| 9522234 | Cabiri | Dec 2016 | B2 |
| 9539384 | Servansky | Jan 2017 | B2 |
| 9539388 | Causey et al. | Jan 2017 | B2 |
| 9539757 | Ramirez et al. | Jan 2017 | B2 |
| 9572926 | Cabiri | Feb 2017 | B2 |
| 9572927 | Bruggemann et al. | Feb 2017 | B2 |
| 9579452 | Adair et al. | Feb 2017 | B2 |
| 9579471 | Carrel et al. | Feb 2017 | B2 |
| 9610407 | Bruggemann et al. | Apr 2017 | B2 |
| 9656019 | Cabiri | May 2017 | B2 |
| 9656021 | Brereton et al. | May 2017 | B2 |
| 9656025 | Bostrom et al. | May 2017 | B2 |
| 9707356 | Hourmand et al. | Jul 2017 | B2 |
| 9744306 | Cowe | Aug 2017 | B2 |
| 9775948 | Bechmann et al. | Oct 2017 | B2 |
| 9782545 | Gross et al. | Oct 2017 | B2 |
| 9789247 | Kamen et al. | Oct 2017 | B2 |
| 9814830 | Mernoe et al. | Nov 2017 | B2 |
| 9814839 | Eaton | Nov 2017 | B2 |
| 9849242 | Henley et al. | Dec 2017 | B2 |
| 9862519 | Deutschle et al. | Jan 2018 | B2 |
| 9999722 | Yodfat et al. | Jun 2018 | B2 |
| 10010681 | Koch et al. | Jul 2018 | B2 |
| 10076356 | Hadvary et al. | Sep 2018 | B2 |
| 10143794 | Lanigan et al. | Dec 2018 | B2 |
| 10149943 | Bar-El et al. | Dec 2018 | B2 |
| D838367 | Norton et al. | Jan 2019 | S |
| 10166335 | Reber et al. | Jan 2019 | B2 |
| 10207048 | Gray et al. | Feb 2019 | B2 |
| 10207051 | Cereda et al. | Feb 2019 | B2 |
| 10227161 | Auerbach | Mar 2019 | B2 |
| 10232116 | Ekman et al. | Mar 2019 | B2 |
| 10258740 | Mcloughlin et al. | Apr 2019 | B2 |
| 10376641 | Hirschel et al. | Aug 2019 | B2 |
| 10376647 | Farris et al. | Aug 2019 | B2 |
| 10434262 | Bendek et al. | Oct 2019 | B2 |
| 10500352 | Grant et al. | Dec 2019 | B2 |
| 10561798 | Holland et al. | Feb 2020 | B2 |
| 10576213 | Gylleby | Mar 2020 | B2 |
| 10576220 | Armes | Mar 2020 | B2 |
| 10583260 | Kemp | Mar 2020 | B2 |
| 10603430 | Shor et al. | Mar 2020 | B2 |
| 10646643 | Cabiri | May 2020 | B2 |
| 10722645 | Kamen et al. | Jul 2020 | B2 |
| 10729847 | Gray et al. | Aug 2020 | B2 |
| 10758679 | Bar-El et al. | Sep 2020 | B2 |
| 10842942 | Iibuchi et al. | Nov 2020 | B2 |
| 11027059 | Niklaus et al. | Jun 2021 | B2 |
| 20010005781 | Bergens et al. | Jun 2001 | A1 |
| 20010018937 | Nemoto | Sep 2001 | A1 |
| 20010025168 | Gross et al. | Sep 2001 | A1 |
| 20010034502 | Moberg et al. | Oct 2001 | A1 |
| 20010041869 | Causey et al. | Nov 2001 | A1 |
| 20020010423 | Gross et al. | Jan 2002 | A1 |
| 20020016569 | Critchlow et al. | Feb 2002 | A1 |
| 20020029018 | Jeffrey | Mar 2002 | A1 |
| 20020040208 | Flaherty et al. | Apr 2002 | A1 |
| 20020055711 | Lavi et al. | May 2002 | A1 |
| 20020055718 | Hunt | May 2002 | A1 |
| 20020065488 | Suzuki et al. | May 2002 | A1 |
| 20020107487 | Preuthun | Aug 2002 | A1 |
| 20020120186 | Keimel | Aug 2002 | A1 |
| 20020123740 | Flaherty et al. | Sep 2002 | A1 |
| 20020151855 | Douglas et al. | Oct 2002 | A1 |
| 20020161332 | Ramey | Oct 2002 | A1 |
| 20020169215 | Meng | Nov 2002 | A1 |
| 20020173748 | McConnell et al. | Nov 2002 | A1 |
| 20020173769 | Gray et al. | Nov 2002 | A1 |
| 20030009133 | Ramey | Jan 2003 | A1 |
| 20030014018 | Giambattista et al. | Jan 2003 | A1 |
| 20030050602 | Pettis et al. | Mar 2003 | A1 |
| 20030069518 | Daley et al. | Apr 2003 | A1 |
| 20030125671 | Aramata et al. | Jul 2003 | A1 |
| 20030130618 | Gray et al. | Jul 2003 | A1 |
| 20030135159 | Daily et al. | Jul 2003 | A1 |
| 20030160683 | Blomquist | Aug 2003 | A1 |
| 20030167039 | Moberg | Sep 2003 | A1 |
| 20030171717 | Farrugia et al. | Sep 2003 | A1 |
| 20030181868 | Swenson | Sep 2003 | A1 |
| 20030199825 | Flaherty et al. | Oct 2003 | A1 |
| 20030216683 | Shekalim | Nov 2003 | A1 |
| 20030236498 | Gross et al. | Dec 2003 | A1 |
| 20040000818 | Preuthun et al. | Jan 2004 | A1 |
| 20040003493 | Adair et al. | Jan 2004 | A1 |
| 20040010207 | Flaherty et al. | Jan 2004 | A1 |
| 20040049160 | Hsieh et al. | Mar 2004 | A1 |
| 20040049161 | Sheam | Mar 2004 | A1 |
| 20040082911 | Tiu et al. | Apr 2004 | A1 |
| 20040092873 | Moberg | May 2004 | A1 |
| 20040116866 | Gorman et al. | Jun 2004 | A1 |
| 20040122359 | Wenz et al. | Jun 2004 | A1 |
| 20040122369 | Schriver et al. | Jun 2004 | A1 |
| 20040127857 | Shemesh et al. | Jul 2004 | A1 |
| 20040135078 | Mandro et al. | Jul 2004 | A1 |
| 20040158172 | Hancock | Aug 2004 | A1 |
| 20040158205 | Savage | Aug 2004 | A1 |
| 20040186419 | Cho | Sep 2004 | A1 |
| 20040186441 | Graf et al. | Sep 2004 | A1 |
| 20040210196 | Bush et al. | Oct 2004 | A1 |
| 20040260233 | Garibotto et al. | Dec 2004 | A1 |
| 20050027255 | Lavi et al. | Feb 2005 | A1 |
| 20050033234 | Sadowski et al. | Feb 2005 | A1 |
| 20050038391 | Wittland et al. | Feb 2005 | A1 |
| 20050065466 | Vedrine | Mar 2005 | A1 |
| 20050065472 | Cindrich et al. | Mar 2005 | A1 |
| 20050071487 | Lu et al. | Mar 2005 | A1 |
| 20050113761 | Faust et al. | May 2005 | A1 |
| 20050124940 | Martin et al. | Jun 2005 | A1 |
| 20050154353 | Alheidt | Jul 2005 | A1 |
| 20050159706 | Wilkinson et al. | Jul 2005 | A1 |
| 20050171476 | Judson et al. | Aug 2005 | A1 |
| 20050171512 | Flaherty | Aug 2005 | A1 |
| 20050177136 | Miller | Aug 2005 | A1 |
| 20050197626 | Moberg et al. | Sep 2005 | A1 |
| 20050197650 | Sugimoto et al. | Sep 2005 | A1 |
| 20050203461 | Flaherty et al. | Sep 2005 | A1 |
| 20050238507 | Diianni et al. | Oct 2005 | A1 |
| 20050245956 | Steinemann et al. | Nov 2005 | A1 |
| 20050283114 | Bresina et al. | Dec 2005 | A1 |
| 20060013716 | Nason et al. | Jan 2006 | A1 |
| 20060030816 | Zubry | Feb 2006 | A1 |
| 20060036216 | Rimlinger et al. | Feb 2006 | A1 |
| 20060095010 | Westbye | May 2006 | A1 |
| 20060095014 | Ethelfeld | May 2006 | A1 |
| 20060122577 | Poulsen et al. | Jun 2006 | A1 |
| 20060124269 | Miyazaki et al. | Jun 2006 | A1 |
| 20060173406 | Hayes et al. | Aug 2006 | A1 |
| 20060173439 | Thorne et al. | Aug 2006 | A1 |
| 20060184154 | Moberg et al. | Aug 2006 | A1 |
| 20060195029 | Shults et al. | Aug 2006 | A1 |
| 20060206054 | Shekalim | Sep 2006 | A1 |
| 20060206057 | Deruntz et al. | Sep 2006 | A1 |
| 20060211982 | Prestrelski et al. | Sep 2006 | A1 |
| 20060229569 | Lavi et al. | Oct 2006 | A1 |
| 20060264888 | Moberg et al. | Nov 2006 | A1 |
| 20060264889 | Moberg et al. | Nov 2006 | A1 |
| 20060264890 | Moberg et al. | Nov 2006 | A1 |
| 20060264894 | Moberg et al. | Nov 2006 | A1 |
| 20060270987 | Peter | Nov 2006 | A1 |
| 20060283465 | Nickel et al. | Dec 2006 | A1 |
| 20060293722 | Slatkine et al. | Dec 2006 | A1 |
| 20070021733 | Hansen et al. | Jan 2007 | A1 |
| 20070025879 | Vandergaw | Feb 2007 | A1 |
| 20070049865 | Radmer et al. | Mar 2007 | A1 |
| 20070073228 | Mernoe et al. | Mar 2007 | A1 |
| 20070079894 | Kraus et al. | Apr 2007 | A1 |
| 20070118405 | Campbell et al. | May 2007 | A1 |
| 20070167912 | Causey et al. | Jul 2007 | A1 |
| 20070179444 | Causey et al. | Aug 2007 | A1 |
| 20070185449 | Mernoe | Aug 2007 | A1 |
| 20070197954 | Keenan | Aug 2007 | A1 |
| 20070197968 | Pongpairochana et al. | Aug 2007 | A1 |
| 20070203454 | Shermer et al. | Aug 2007 | A1 |
| 20070233038 | Pruitt et al. | Oct 2007 | A1 |
| 20070265568 | Tsals et al. | Nov 2007 | A1 |
| 20070282269 | Carter et al. | Dec 2007 | A1 |
| 20080021439 | Brittingham et al. | Jan 2008 | A1 |
| 20080033367 | Haury et al. | Feb 2008 | A1 |
| 20080033369 | Kohlbrenner et al. | Feb 2008 | A1 |
| 20080033393 | Edwards et al. | Feb 2008 | A1 |
| 20080051711 | Mounce et al. | Feb 2008 | A1 |
| 20080051730 | Bikovsky | Feb 2008 | A1 |
| 20080059133 | Edwards et al. | Mar 2008 | A1 |
| 20080097326 | Moberg et al. | Apr 2008 | A1 |
| 20080097381 | Moberg et al. | Apr 2008 | A1 |
| 20080097387 | Spector | Apr 2008 | A1 |
| 20080108951 | Jerde et al. | May 2008 | A1 |
| 20080119795 | Erskine | May 2008 | A1 |
| 20080140006 | Eskuri et al. | Jun 2008 | A1 |
| 20080140014 | Miller et al. | Jun 2008 | A1 |
| 20080140018 | Enggaard et al. | Jun 2008 | A1 |
| 20080147004 | Mann et al. | Jun 2008 | A1 |
| 20080167641 | Hansen et al. | Jul 2008 | A1 |
| 20080188813 | Miller et al. | Aug 2008 | A1 |
| 20080208138 | Lim et al. | Aug 2008 | A1 |
| 20080215006 | Thorkild | Sep 2008 | A1 |
| 20080215013 | Felix-Faure | Sep 2008 | A1 |
| 20080215015 | Cindrich et al. | Sep 2008 | A1 |
| 20080221523 | Moberg et al. | Sep 2008 | A1 |
| 20080243087 | Enggaard et al. | Oct 2008 | A1 |
| 20080249473 | Rutti et al. | Oct 2008 | A1 |
| 20080262436 | Olson | Oct 2008 | A1 |
| 20080269687 | Chong et al. | Oct 2008 | A1 |
| 20080269723 | Mastrototaro et al. | Oct 2008 | A1 |
| 20080274630 | Shelton et al. | Nov 2008 | A1 |
| 20080294143 | Tanaka et al. | Nov 2008 | A1 |
| 20080306449 | Kristensen et al. | Dec 2008 | A1 |
| 20080312601 | Cane | Dec 2008 | A1 |
| 20080319383 | Byland et al. | Dec 2008 | A1 |
| 20080319416 | Yodfat et al. | Dec 2008 | A1 |
| 20090012478 | Weston | Jan 2009 | A1 |
| 20090041805 | Walker | Feb 2009 | A1 |
| 20090048347 | Cohen et al. | Feb 2009 | A1 |
| 20090054750 | Jennewine | Feb 2009 | A1 |
| 20090069784 | Estes et al. | Mar 2009 | A1 |
| 20090076383 | Toews et al. | Mar 2009 | A1 |
| 20090076453 | Mejlhede et al. | Mar 2009 | A1 |
| 20090088694 | Carter et al. | Apr 2009 | A1 |
| 20090088731 | Campbell et al. | Apr 2009 | A1 |
| 20090093763 | Gonnelli et al. | Apr 2009 | A1 |
| 20090093792 | Gross et al. | Apr 2009 | A1 |
| 20090093793 | Gross et al. | Apr 2009 | A1 |
| 20090105650 | Wiegel et al. | Apr 2009 | A1 |
| 20090105663 | Brand et al. | Apr 2009 | A1 |
| 20090124977 | Jensen | May 2009 | A1 |
| 20090143730 | De et al. | Jun 2009 | A1 |
| 20090143735 | De et al. | Jun 2009 | A1 |
| 20090149830 | Spector | Jun 2009 | A1 |
| 20090182277 | Carter | Jul 2009 | A1 |
| 20090182284 | Morgan | Jul 2009 | A1 |
| 20090204076 | Liversidge | Aug 2009 | A1 |
| 20090209896 | Selevan | Aug 2009 | A1 |
| 20090234319 | Marksteiner | Sep 2009 | A1 |
| 20090240240 | Hines et al. | Sep 2009 | A1 |
| 20090253973 | Bashan et al. | Oct 2009 | A1 |
| 20090259176 | Yairi | Oct 2009 | A1 |
| 20090281585 | Katzman et al. | Nov 2009 | A1 |
| 20090299288 | Sie et al. | Dec 2009 | A1 |
| 20090299290 | Moberg | Dec 2009 | A1 |
| 20090299397 | Ruan et al. | Dec 2009 | A1 |
| 20090326459 | Shipway et al. | Dec 2009 | A1 |
| 20090326509 | Muse et al. | Dec 2009 | A1 |
| 20100010455 | Elahi et al. | Jan 2010 | A1 |
| 20100018334 | Lessing | Jan 2010 | A1 |
| 20100030156 | Beebe et al. | Feb 2010 | A1 |
| 20100030198 | Beebe | Feb 2010 | A1 |
| 20100049128 | Mckenzie et al. | Feb 2010 | A1 |
| 20100049144 | Mcconnell et al. | Feb 2010 | A1 |
| 20100057057 | Hayter et al. | Mar 2010 | A1 |
| 20100076382 | Weston | Mar 2010 | A1 |
| 20100076412 | Rush et al. | Mar 2010 | A1 |
| 20100094255 | Nycz et al. | Apr 2010 | A1 |
| 20100100076 | Rush et al. | Apr 2010 | A1 |
| 20100100077 | Rush et al. | Apr 2010 | A1 |
| 20100106098 | Atterbury et al. | Apr 2010 | A1 |
| 20100121314 | Iobbi | May 2010 | A1 |
| 20100137790 | Yodfat | Jun 2010 | A1 |
| 20100137831 | Tsals | Jun 2010 | A1 |
| 20100145303 | Yodfat et al. | Jun 2010 | A1 |
| 20100145305 | Alon | Jun 2010 | A1 |
| 20100160894 | Julian et al. | Jun 2010 | A1 |
| 20100162548 | Leidig | Jul 2010 | A1 |
| 20100168607 | Miesel | Jul 2010 | A1 |
| 20100168683 | Cabiri | Jul 2010 | A1 |
| 20100198157 | Gyrn et al. | Aug 2010 | A1 |
| 20100204657 | Yodfat et al. | Aug 2010 | A1 |
| 20100234767 | Sarstedt | Sep 2010 | A1 |
| 20100234830 | Straessler et al. | Sep 2010 | A1 |
| 20100241065 | Moberg et al. | Sep 2010 | A1 |
| 20100241103 | Kraft et al. | Sep 2010 | A1 |
| 20100256486 | Savage | Oct 2010 | A1 |
| 20100264931 | Lindegger et al. | Oct 2010 | A1 |
| 20100268169 | Llewellyn-Hyde et al. | Oct 2010 | A1 |
| 20100274112 | Hoss et al. | Oct 2010 | A1 |
| 20100274192 | Mernoe | Oct 2010 | A1 |
| 20100280499 | Yodfat et al. | Nov 2010 | A1 |
| 20100331826 | Field et al. | Dec 2010 | A1 |
| 20110034900 | Yodfat et al. | Feb 2011 | A1 |
| 20110054399 | Chong et al. | Mar 2011 | A1 |
| 20110054400 | Chong et al. | Mar 2011 | A1 |
| 20110066131 | Cabiri | Mar 2011 | A1 |
| 20110092915 | Olson et al. | Apr 2011 | A1 |
| 20110112504 | Causey et al. | May 2011 | A1 |
| 20110125056 | Merchant | May 2011 | A1 |
| 20110160654 | Hanson et al. | Jun 2011 | A1 |
| 20110160666 | Hanson et al. | Jun 2011 | A1 |
| 20110160669 | Gyrn et al. | Jun 2011 | A1 |
| 20110172645 | Moga et al. | Jul 2011 | A1 |
| 20110172745 | Na et al. | Jul 2011 | A1 |
| 20110178463 | Cabiri | Jul 2011 | A1 |
| 20110178472 | Cabiri | Jul 2011 | A1 |
| 20110201998 | Pongpairochana et al. | Aug 2011 | A1 |
| 20110224616 | Slate et al. | Sep 2011 | A1 |
| 20110224646 | Yodfat et al. | Sep 2011 | A1 |
| 20110238031 | Adair et al. | Sep 2011 | A1 |
| 20110245773 | Estes et al. | Oct 2011 | A1 |
| 20110270160 | Mernoe | Nov 2011 | A1 |
| 20110282282 | Lorenzen et al. | Nov 2011 | A1 |
| 20110282296 | Harms et al. | Nov 2011 | A1 |
| 20110288526 | Wei | Nov 2011 | A1 |
| 20110295205 | Kaufmann et al. | Dec 2011 | A1 |
| 20110313238 | Reichenbach et al. | Dec 2011 | A1 |
| 20110319861 | Wilk | Dec 2011 | A1 |
| 20110319919 | Curry et al. | Dec 2011 | A1 |
| 20120004602 | Hanson et al. | Jan 2012 | A1 |
| 20120010594 | Holt et al. | Jan 2012 | A1 |
| 20120022344 | Kube | Jan 2012 | A1 |
| 20120022496 | Causey et al. | Jan 2012 | A1 |
| 20120022499 | Anderson et al. | Jan 2012 | A1 |
| 20120029431 | Hwang et al. | Feb 2012 | A1 |
| 20120035546 | Cabiri | Feb 2012 | A1 |
| 20120041364 | Smith | Feb 2012 | A1 |
| 20120041387 | Brüggemann et al. | Feb 2012 | A1 |
| 20120041414 | Estes et al. | Feb 2012 | A1 |
| 20120071828 | Tojo et al. | Mar 2012 | A1 |
| 20120096953 | Bente et al. | Apr 2012 | A1 |
| 20120096954 | Vazquez et al. | Apr 2012 | A1 |
| 20120101436 | Bazargan et al. | Apr 2012 | A1 |
| 20120108933 | Liang et al. | May 2012 | A1 |
| 20120109059 | Ranalletta et al. | May 2012 | A1 |
| 20120118777 | Kakiuchi et al. | May 2012 | A1 |
| 20120123387 | Gonzalez et al. | May 2012 | A1 |
| 20120129362 | Hampo et al. | May 2012 | A1 |
| 20120160033 | Kow et al. | Jun 2012 | A1 |
| 20120165733 | Bazargan et al. | Jun 2012 | A1 |
| 20120165780 | Bazargan et al. | Jun 2012 | A1 |
| 20120172817 | Brüggemann et al. | Jul 2012 | A1 |
| 20120184917 | Bom et al. | Jul 2012 | A1 |
| 20120226234 | Bazargan et al. | Sep 2012 | A1 |
| 20120238961 | Julian et al. | Sep 2012 | A1 |
| 20120259282 | Alderete et al. | Oct 2012 | A1 |
| 20130012875 | Gross et al. | Jan 2013 | A1 |
| 20130068319 | Plumptre et al. | Mar 2013 | A1 |
| 20130085457 | Schiff et al. | Apr 2013 | A1 |
| 20130089992 | Yang | Apr 2013 | A1 |
| 20130096509 | Avery et al. | Apr 2013 | A1 |
| 20130110049 | Cronenberg et al. | May 2013 | A1 |
| 20130131589 | Mudd et al. | May 2013 | A1 |
| 20130131604 | Avery | May 2013 | A1 |
| 20130133438 | Kow et al. | May 2013 | A1 |
| 20130172808 | Gilbert | Jul 2013 | A1 |
| 20130190693 | Ekman et al. | Jul 2013 | A1 |
| 20130200549 | Felts et al. | Aug 2013 | A1 |
| 20130204187 | Avery et al. | Aug 2013 | A1 |
| 20130204191 | Cindrich et al. | Aug 2013 | A1 |
| 20130237953 | Kow et al. | Sep 2013 | A1 |
| 20130245595 | Kow et al. | Sep 2013 | A1 |
| 20130245596 | Cabiri et al. | Sep 2013 | A1 |
| 20130245604 | Kouyoumjian et al. | Sep 2013 | A1 |
| 20130253419 | Favreau | Sep 2013 | A1 |
| 20130253420 | Favreau | Sep 2013 | A1 |
| 20130253421 | Favreau | Sep 2013 | A1 |
| 20130253434 | Cabiri | Sep 2013 | A1 |
| 20130267895 | Hemmingsen | Oct 2013 | A1 |
| 20130296799 | Degtiar et al. | Nov 2013 | A1 |
| 20130296824 | Mo et al. | Nov 2013 | A1 |
| 20130304021 | Cabiri et al. | Nov 2013 | A1 |
| 20130310753 | Cabiri | Nov 2013 | A1 |
| 20130310807 | Adair et al. | Nov 2013 | A1 |
| 20130323699 | Edwards et al. | Dec 2013 | A1 |
| 20130331791 | Gross et al. | Dec 2013 | A1 |
| 20130338584 | Mounce et al. | Dec 2013 | A1 |
| 20140018735 | Causey et al. | Jan 2014 | A1 |
| 20140031747 | Ardehali | Jan 2014 | A1 |
| 20140055073 | Favreau | Feb 2014 | A1 |
| 20140055076 | Favreau | Feb 2014 | A1 |
| 20140058349 | Bazargan et al. | Feb 2014 | A1 |
| 20140083517 | Moia et al. | Mar 2014 | A1 |
| 20140094755 | Bazargan et al. | Apr 2014 | A1 |
| 20140121633 | Causey et al. | May 2014 | A1 |
| 20140128807 | Moberg et al. | May 2014 | A1 |
| 20140128835 | Moberg et al. | May 2014 | A1 |
| 20140135692 | Alderete et al. | May 2014 | A1 |
| 20140135694 | Moberg et al. | May 2014 | A1 |
| 20140142499 | Moberg et al. | May 2014 | A1 |
| 20140148784 | Anderson et al. | May 2014 | A1 |
| 20140148785 | Moberg et al. | May 2014 | A1 |
| 20140163522 | Alderete et al. | Jun 2014 | A1 |
| 20140163526 | Cabiri et al. | Jun 2014 | A1 |
| 20140171881 | Cabiri | Jun 2014 | A1 |
| 20140174223 | Gross et al. | Jun 2014 | A1 |
| 20140194819 | Maule et al. | Jul 2014 | A1 |
| 20140194854 | Tsals | Jul 2014 | A1 |
| 20140207064 | Yavorsky | Jul 2014 | A1 |
| 20140207065 | Yavorsky | Jul 2014 | A1 |
| 20140207066 | Yavorsky | Jul 2014 | A1 |
| 20140207104 | Vouillamoz et al. | Jul 2014 | A1 |
| 20140213975 | Clemente et al. | Jul 2014 | A1 |
| 20140214001 | Mortazavi | Jul 2014 | A1 |
| 20140228768 | Eggert et al. | Aug 2014 | A1 |
| 20140236087 | Alderete et al. | Aug 2014 | A1 |
| 20140243786 | Gilbert et al. | Aug 2014 | A1 |
| 20140261758 | Wlodarczyk et al. | Sep 2014 | A1 |
| 20140343503 | Holmqvist | Nov 2014 | A1 |
| 20140364808 | Niklaus et al. | Dec 2014 | A1 |
| 20150005703 | Hutchinson et al. | Jan 2015 | A1 |
| 20150073344 | Van Damme et al. | Mar 2015 | A1 |
| 20150088071 | Cabiri | Mar 2015 | A1 |
| 20150112278 | Ray et al. | Apr 2015 | A1 |
| 20150119798 | Gross et al. | Apr 2015 | A1 |
| 20150157806 | Knutsson | Jun 2015 | A1 |
| 20150165129 | Row | Jun 2015 | A1 |
| 20150202375 | Schabbach et al. | Jul 2015 | A1 |
| 20150374926 | Gross et al. | Dec 2015 | A1 |
| 20160030665 | Cabiri | Feb 2016 | A1 |
| 20160051756 | Cabiri | Feb 2016 | A1 |
| 20160144117 | Chun | May 2016 | A1 |
| 20160151586 | Kemp | Jun 2016 | A1 |
| 20160175515 | Mccullough | Jun 2016 | A1 |
| 20160184512 | Marbet et al. | Jun 2016 | A1 |
| 20160193406 | Cabiri | Jul 2016 | A1 |
| 20160199590 | Schabbach et al. | Jul 2016 | A1 |
| 20160213840 | Schabbach et al. | Jul 2016 | A1 |
| 20160220755 | Lanigan et al. | Aug 2016 | A1 |
| 20160228652 | Cabiri et al. | Aug 2016 | A1 |
| 20160296713 | Schader et al. | Oct 2016 | A1 |
| 20160296716 | Cabiri et al. | Oct 2016 | A1 |
| 20160331900 | Wei | Nov 2016 | A1 |
| 20160339168 | Hutchinson et al. | Nov 2016 | A1 |
| 20160346478 | Bar-El et al. | Dec 2016 | A1 |
| 20160354553 | Anderson et al. | Dec 2016 | A1 |
| 20170007774 | Brockmeier | Jan 2017 | A1 |
| 20170043092 | Murakami et al. | Feb 2017 | A1 |
| 20170058349 | Levy et al. | Mar 2017 | A1 |
| 20170175859 | Brockmeier | Jun 2017 | A1 |
| 20170246399 | Forlani et al. | Aug 2017 | A1 |
| 20170246403 | Cowe et al. | Aug 2017 | A1 |
| 20180028765 | Waller et al. | Feb 2018 | A1 |
| 20180133413 | Grant et al. | May 2018 | A1 |
| 20180214637 | Kemp et al. | Aug 2018 | A1 |
| 20180304029 | Koch et al. | Oct 2018 | A1 |
| 20190022306 | Gibson et al. | Jan 2019 | A1 |
| 20190060578 | Farris et al. | Feb 2019 | A1 |
| 20190071217 | Brown et al. | Mar 2019 | A1 |
| 20190099549 | Lanigan et al. | Apr 2019 | A1 |
| 20190175821 | Kamen et al. | Jun 2019 | A1 |
| 20190224415 | Dugand et al. | Jul 2019 | A1 |
| 20190240417 | Hostettler et al. | Aug 2019 | A1 |
| 20190328968 | Giambattista | Oct 2019 | A1 |
| 20200009323 | Nair et al. | Jan 2020 | A1 |
| 20200164151 | Farris et al. | May 2020 | A1 |
| 20200215270 | Ogawa et al. | Jul 2020 | A1 |
| 20200297929 | Zhang | Sep 2020 | A1 |
| 20200360602 | Gray et al. | Nov 2020 | A1 |
| 20210138157 | Bar-El et al. | May 2021 | A1 |
| 20210220551 | Dowd et al. | Jul 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 1505535 | Jun 2004 | CN |
| 1747683 | Mar 2006 | CN |
| 1863566 | Nov 2006 | CN |
| 101090749 | Dec 2007 | CN |
| 101227943 | Jul 2008 | CN |
| 101448536 | Jun 2009 | CN |
| 101522235 | Sep 2009 | CN |
| 101541362 | Sep 2009 | CN |
| 101641126 | Feb 2010 | CN |
| 201692438 | Jan 2011 | CN |
| 201941304 | Aug 2011 | CN |
| 102186733 | Sep 2011 | CN |
| 102378638 | Mar 2012 | CN |
| 105102025 | Nov 2015 | CN |
| 0855313 | Nov 1952 | DE |
| 1064693 | Sep 1959 | DE |
| 19518807 | Dec 1995 | DE |
| 19717107 | Nov 1998 | DE |
| 0017412 | Oct 1980 | EP |
| 0222656 | May 1987 | EP |
| 0401179 | Dec 1990 | EP |
| 0851774 | Jul 1998 | EP |
| 0925082 | Jun 1999 | EP |
| 1003581 | May 2000 | EP |
| 1124600 | Aug 2001 | EP |
| 1219312 | Jul 2002 | EP |
| 1472477 | Nov 2004 | EP |
| 1530979 | May 2005 | EP |
| 1666080 | Jun 2006 | EP |
| 1372762 | Feb 2007 | EP |
| 1974759 | Oct 2008 | EP |
| 2060606 | May 2009 | EP |
| 2140897 | Jan 2010 | EP |
| 2173413 | Apr 2010 | EP |
| 2185227 | May 2010 | EP |
| 2192935 | Jun 2010 | EP |
| 2361648 | Aug 2011 | EP |
| 2364739 | Sep 2011 | EP |
| 2393534 | Dec 2011 | EP |
| 2452708 | May 2012 | EP |
| 2498589 | Sep 2012 | EP |
| 2574355 | Apr 2013 | EP |
| 2393535 | Mar 2015 | EP |
| 2878321 | Jun 2015 | EP |
| 2886144 | Jun 2015 | EP |
| 1904130 | Mar 2016 | EP |
| 2991705 | Mar 2016 | EP |
| 3266478 | Jan 2018 | EP |
| 2819724 | Mar 2019 | EP |
| 2770136 | Apr 1999 | FR |
| 2436526 | Oct 2007 | GB |
| 62-112566 | May 1987 | JP |
| 01-172843 | Dec 1989 | JP |
| 05-062828 | Mar 1993 | JP |
| 07-194701 | Aug 1995 | JP |
| 3035448 | Mar 1997 | JP |
| 09-505758 | Jun 1997 | JP |
| 11-507260 | Jun 1999 | JP |
| 2000-107289 | Apr 2000 | JP |
| 2000-515394 | Nov 2000 | JP |
| 2001-512992 | Aug 2001 | JP |
| 2002-505601 | Feb 2002 | JP |
| 2002-507459 | Mar 2002 | JP |
| 2002-528676 | Sep 2002 | JP |
| 2003-501157 | Jan 2003 | JP |
| 2003-534061 | Nov 2003 | JP |
| 2004-501721 | Jan 2004 | JP |
| 2004-512100 | Apr 2004 | JP |
| 2003-527138 | Aug 2005 | JP |
| 2005-523127 | Aug 2005 | JP |
| 2005-527249 | Sep 2005 | JP |
| 2005-270629 | Oct 2005 | JP |
| 2006-507067 | Mar 2006 | JP |
| 2006-510450 | Mar 2006 | JP |
| 2006-525046 | Nov 2006 | JP |
| 2007-509661 | Apr 2007 | JP |
| 2007-306990 | Nov 2007 | JP |
| 2008-534131 | Aug 2008 | JP |
| 2008-220961 | Sep 2008 | JP |
| 2009-502273 | Jan 2009 | JP |
| 2009-101093 | May 2009 | JP |
| 2010-501281 | Jan 2010 | JP |
| 2010-540054 | Dec 2010 | JP |
| 2010-540156 | Dec 2010 | JP |
| 2011-136153 | Jul 2011 | JP |
| 2012-100927 | May 2012 | JP |
| 4947871 | Jun 2012 | JP |
| 2013-500811 | Jan 2013 | JP |
| 2013-505433 | Feb 2013 | JP |
| 2013-517095 | May 2013 | JP |
| 2013-519473 | May 2013 | JP |
| 2013-530778 | Aug 2013 | JP |
| 2013-531520 | Aug 2013 | JP |
| 2013-531540 | Aug 2013 | JP |
| 2014-030489 | Feb 2014 | JP |
| 2014-515669 | Jul 2014 | JP |
| 2014-518743 | Aug 2014 | JP |
| 2014-521443 | Aug 2014 | JP |
| 2014-525339 | Sep 2014 | JP |
| 2015-514486 | May 2015 | JP |
| 2016-525428 | Aug 2016 | JP |
| 2016-530016 | Sep 2016 | JP |
| 9009202 | Aug 1990 | WO |
| 9307922 | Apr 1993 | WO |
| 9407553 | Apr 1994 | WO |
| 9415660 | Jul 1994 | WO |
| 9513838 | May 1995 | WO |
| 9609083 | Mar 1996 | WO |
| 9632975 | Oct 1996 | WO |
| 9700091 | Jan 1997 | WO |
| 9710012 | Mar 1997 | WO |
| 9721457 | Jun 1997 | WO |
| 9733638 | Sep 1997 | WO |
| 9857683 | Dec 1998 | WO |
| 9857686 | Dec 1998 | WO |
| 9929151 | Jun 1999 | WO |
| 9938554 | Aug 1999 | WO |
| 9959665 | Nov 1999 | WO |
| 0025844 | May 2000 | WO |
| 0069509 | Nov 2000 | WO |
| 0130415 | May 2001 | WO |
| 0130421 | May 2001 | WO |
| 0170304 | Sep 2001 | WO |
| 0172357 | Oct 2001 | WO |
| 0187384 | Nov 2001 | WO |
| 0189607 | Nov 2001 | WO |
| 0189613 | Nov 2001 | WO |
| 0202165 | Jan 2002 | WO |
| 0204049 | Jan 2002 | WO |
| 0234315 | May 2002 | WO |
| 0238204 | May 2002 | WO |
| 0256934 | Jul 2002 | WO |
| 0256943 | Jul 2002 | WO |
| 0272182 | Sep 2002 | WO |
| 0362672 | Jul 2003 | WO |
| 0390833 | Nov 2003 | WO |
| 2004000397 | Dec 2003 | WO |
| 2004032990 | Apr 2004 | WO |
| 2004098684 | Nov 2004 | WO |
| 2004105841 | Dec 2004 | WO |
| 2005018703 | Mar 2005 | WO |
| 2005037350 | Apr 2005 | WO |
| 2005070485 | Aug 2005 | WO |
| 2005072795 | Aug 2005 | WO |
| 2006018617 | Feb 2006 | WO |
| 2006037434 | Apr 2006 | WO |
| 2006052737 | May 2006 | WO |
| 2006069380 | Jun 2006 | WO |
| 2006102676 | Sep 2006 | WO |
| 2006104806 | Oct 2006 | WO |
| 2006121921 | Nov 2006 | WO |
| 2007017052 | Feb 2007 | WO |
| 2007051563 | May 2007 | WO |
| 2007056504 | May 2007 | WO |
| 2007066152 | Jun 2007 | WO |
| 2007073228 | Jun 2007 | WO |
| 2007119178 | Oct 2007 | WO |
| 2008001377 | Jan 2008 | WO |
| 2008014908 | Feb 2008 | WO |
| 2008057976 | May 2008 | WO |
| 2008072229 | Jun 2008 | WO |
| 2008076459 | Jun 2008 | WO |
| 2008078318 | Jul 2008 | WO |
| 2009019438 | Feb 2009 | WO |
| 2009022132 | Feb 2009 | WO |
| 2009043000 | Apr 2009 | WO |
| 2009043564 | Apr 2009 | WO |
| 2009044401 | Apr 2009 | WO |
| 2009046989 | Apr 2009 | WO |
| 2009069064 | Jun 2009 | WO |
| 2009125398 | Oct 2009 | WO |
| 2009144085 | Dec 2009 | WO |
| 2010078227 | Jul 2010 | WO |
| 2010078242 | Jul 2010 | WO |
| 2010089313 | Aug 2010 | WO |
| 2011075105 | Jun 2011 | WO |
| 2011090955 | Jul 2011 | WO |
| 2011090956 | Jul 2011 | WO |
| WO 2011101378 | Aug 2011 | WO |
| 2011110872 | Sep 2011 | WO |
| 2011124631 | Oct 2011 | WO |
| 2011129175 | Oct 2011 | WO |
| 2011131778 | Oct 2011 | WO |
| 2011131780 | Oct 2011 | WO |
| 2011131781 | Oct 2011 | WO |
| 2011133823 | Oct 2011 | WO |
| 2011156373 | Dec 2011 | WO |
| 2012003221 | Jan 2012 | WO |
| 2012032411 | Mar 2012 | WO |
| 2012040528 | Mar 2012 | WO |
| 2012145752 | Oct 2012 | WO |
| 2012160157 | Nov 2012 | WO |
| 2012168691 | Dec 2012 | WO |
| 2013036602 | Mar 2013 | WO |
| 2013058697 | Apr 2013 | WO |
| 2013115843 | Aug 2013 | WO |
| 2014132293 | Sep 2014 | WO |
| 2014179117 | Nov 2014 | WO |
| 2014179774 | Nov 2014 | WO |
| 2014194183 | Dec 2014 | WO |
| 2015048791 | Apr 2015 | WO |
| 2015048803 | Apr 2015 | WO |
| 2015078868 | Jun 2015 | WO |
| 2015091758 | Jun 2015 | WO |
| 2015091850 | Jun 2015 | WO |
| 2015114158 | Aug 2015 | WO |
| 2015114428 | Aug 2015 | WO |
| 2015118358 | Aug 2015 | WO |
| 2015163009 | Oct 2015 | WO |
| 2016087626 | Jun 2016 | WO |
| 2016087627 | Jun 2016 | WO |
| 2016141082 | Sep 2016 | WO |
| 2017022639 | Feb 2017 | WO |
| 2017161076 | Sep 2017 | WO |
| 2018222521 | Dec 2018 | WO |
| 2019224782 | Nov 2019 | WO |
| 2020120087 | Jun 2020 | WO |
| 2020193468 | Oct 2020 | WO |
| Entry |
|---|
| US 8,333,733 B2, 12/2012, Lanigan et al. (withdrawn) |
| Office Action dated Feb. 20, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
| Office Action dated Nov. 6, 2015 in U.S. Appl. No. 14/715,791 by Cabiri. |
| Office Action dated Oct. 6, 2020 in Japanese Application No. 2018-538527. |
| Partial European Search Report dated Nov. 24, 2015 in EP Application No. 14166592.7. |
| Search Report dated Oct. 14, 2016 in CN Application No. 2014101783742. |
| U.S. Appl. No. 12/559,563, filed Sep. 15, 2009. |
| U.S. Appl. No. 12/689,249, filed Jan. 19, 2010. |
| U.S. Appl. No. 12/689,250, filed Jan. 19, 2010. |
| U.S. Appl. No. 13/429,840 by Cabiri, filed Mar. 26, 2012. |
| U.S. Appl. No. 13/472,112 by Cabiri, filed May 15, 2012. |
| U.S. Appl. No. 13/521,167 by Cabiri, filed Jul. 9, 2012. |
| U.S. Appl. No. 13/521,181 by Cabiri, filed Jul. 9, 2012. |
| U.S. Appl. No. 13/643,470 by Alon, filed Oct. 25, 2012. |
| U.S. Appl. No. 13/733,516 by Cabiri, filed Jan. 3, 2013. |
| U.S. Appl. No. 13/873,335 by Filman, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/874,017 by Cabiri, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/874,085 by Cabiri, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/874,121 by Degtiar, filed Apr. 30, 2013. |
| U.S. Appl. No. 13/892,905 by Cabiri, filed May 13, 2013. |
| U.S. Appl. No. 13/964,651 by Gross, filed Aug. 12, 2013. |
| U.S. Appl. No. 14/193,692 by Gross, filed Feb. 28, 2014. |
| U.S. Appl. No. 14/258,661 by Cabiri, filed Apr. 22, 2014. |
| U.S. Appl. No. 14/553,399 by Cabiri, filed Nov. 25, 2014. |
| U.S. Appl. No. 14/593,051 by Gross, filed Jan. 9, 2015. |
| U.S. Appl. No. 14/638,525 by Filman, filed Mar. 4, 2015. |
| U.S. Appl. No. 14/683,193 by Cabiri, filed Apr. 10, 2015. |
| U.S. Appl. No. 14/715,791 by Cabiri, filed May 19, 2015. |
| U.S. Appl. No. 14/725,009 by Bar-El, filed May 29, 2015. |
| U.S. Appl. No. 14/850,450 by Gross, filed Sep. 10, 2015. |
| U.S. Appl. No. 14/861,478 by Cabiri, filed Sep. 22, 2015. |
| U.S. Appl. No. 14/880,673 by Cabiri, filed Oct. 12, 2015. |
| U.S. Appl. No. 29/479,307 by Norton, filed Jan. 14, 2014. |
| U.S. Appl. No. 60/997,459, filed Oct. 2, 2007. |
| West Introduces the Daikyo Crystal Zenith RU Prefillable Syringe, Pharmaceutical Online, Jun. 2008, downloaded from webpage: http://www.pharmaceuticalonline.com/article.mvc/west-introduces-prefillab-le-syringe-system, Download date: Jan. 2009, original posting date: Jun. 2008, 2 pages. |
| Communication Pursuant to Rules 161 and 162 dated Apr. 6, 2018 in EP Application No. 16784688.0. |
| Copaxone(Registered), Innovative Drugs, Teva Pharmaceuticals, downloaded from webpage: http://levapharm.com/copaxone/, Download date: Jan. 2009, original posting date: unknown, 3 pages. |
| Daikyo Crystal Zenith(Registered) polymer, Manufactured by Daikyo Seiko, Lid. (Jun. 25, 2008). |
| Definition of Monolithic. In Merriam-Webster's online dictionary. Retrieved from https://www.merriam-webster.com/dictionary/monolithic (Year: 2021). |
| English translation of an Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X. |
| English translation of an Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X. |
| European Search Report (Partial) dated Mar. 8, 2017 in EP Application 16193157.1. |
| Extended European Search Report dated Aug. 7, 2014 in EP Application No. 1417477.4. |
| Extended European Search Report dated Feb. 12, 2018 in EP Application No. 17191756.0. |
| Extended European Search Report dated Feb. 13, 2017 in EP Application No. 16171626.1. |
| Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166591.9. |
| Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166596.8. |
| Extended European Search Report dated Jul. 3, 2017 in EP Application No. 16190054.3. |
| Extended European Search Report dated Mar. 27, 2014 in EP Application No. 14154717.4. |
| Extended European Search Report dated Mar. 8, 2016 in EP Application No. 14166592.7. |
| Extended European Search Report dated Nov. 10, 2016 in EP Application No. 08808111.2. |
| Extended European Search Report dated Jul. 28, 2020 in European Application No. 20172466.3. |
| Extended Search Report dated Aug. 7, 2014 in EP Application No. 14171477.4. |
| Extended Search Report dated Jul. 7, 2017 in EP Application No. 16193157.1. |
| Int'l Preliminary Report on Patentability dated Nov. 22, 2017 in Int'l Application No. PCT/US2016/068371. |
| Int'l Search Report and Written Opinion dated Jan. 12, 2011 in Int'l Application No. PCT/US2010/048556; Written Opinion. |
| Int'l Search Report and Written Opinion dated Jan. 26, 2017 in Int'l Application No. PCT/US2016/056213. |
| Int'l Search Report and Written Opinion dated Mar. 27, 2017 in Int'l Application No. PCT/US2016/056247. |
| Int'l Search Report and Written Opinion dated Apr. 21, 2017 in Int'l Application No. PCT/US2016/068367. |
| Int'l Search Report and Written Opinion dated May 15, 2017 in Int'l Application No. PCT/US2016/068371. |
| Int'l Search Report and Written Opinion dated Jul. 6, 2017 in Int'l Application No. PCT/US2017/022966. |
| Int'l Search Report and Written Opinion dated Nov. 28, 2016 in Int'l Application No. PCT/US2016/056218. |
| Int'l Search Report and Written Opinion dated Dec. 2, 2016 in Int'l Application No. PCT/US2016/056210. |
| Int'l Search Report and Written Opinion dated Dec. 5, 2016 in Int'l Application No. PCT/US2016/056233. |
| Int'l Search Report and Written Opinion dated Dec. 8, 2016 in Inl'l Application No. PCT/US2016/056227. |
| Int'l Search Report and Written Opinion dated Dec. 15, 2016 in Inl'l Application No. PCT/US2016/056258. |
| Int'l Search Repport (Partial), dated Dec. 20, 2016 in Int'l Application No. PCT/US2016/056247. |
| Int'l Preliminary Report on Patentability dated Jan. 8, 2018 in Int'l Application No. POT/US2016/056218. |
| Int'l Preliminary Report on Patentability dated Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312. |
| Int'l Preliminary Report on Patentability dated Aug. 2, 2012 in Int'l Application No. PCT/US2011/021604. |
| Int'l Preliminary Report on Patentability dated Feb. 7, 2013 in Int'l Application No. PCT/US11/21605. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056210. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056213. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056223. |
| Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056227. |
| Int'l Preliminary Report on Patentability dated Jul. 16, 2015 in Int'l Application No. PCT/US2013/078040. |
| Int'l Preliminary Report on Patentability dated May 14, 2015 in Int'l Application No. PCT/US2013/065211. |
| Int'l Preliminary Report on Patentability dated Nov. 27, 2014 in Int'l Application No. PCT/US2013/039465. |
| Int'l Preliminary Report on Patentability dated Nov. 30, 2017 in Int'l Application No. PCT/US2016/068367. |
| Int'l Preliminary Report on Patentability dated Nov. 9, 2018 in Int'l Application No. PCT/US2016/056238. |
| Int'l Preliminary Report on Patentability dated Oct. 9, 2014 in Int'l Application No. PCT/US2013/033118. |
| Int'l Preliminary Report on Patentability dated Sep. 1, 2011 in Int'l Application No. PCT/US2010/048556. |
| Int'l Search Report and Written Opinion dated Apr. 3, 2014 in Int'l Application No. PCT/US2013/078040. |
| Int'l Search Report and Written Opinion dated Aug. 5, 2013 in Int'l Application No. PCT/US2013/033118. |
| Int'l Search Report and Written Opinion dated Jan. 7, 2014 in Int'l Application No. PCT/US2013/065211. |
| Office Action dated Jun. 9, 2017 in EP Application No. 14166591.9. |
| Office Action dated Jun. 9, 2017 in EP Application No. 14166596.8. |
| Office Action dated Mar. 1, 2018 in EP Application No. 14166592.7. |
| Office Action dated Mar. 10, 2015 in CN Application No. 201180006567.4. |
| Office Action dated Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Mar. 10, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
| Office Action dated Mar. 30, 2018 in U.S. Appl. No. 14/850,450 by Gross. |
| Office Action dated Mar. 31, 2015 in JP Application No. 2012-550068. |
| Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X. |
| Office Action dated May 1, 2015 in U.S. Appl. No. 14/638,525 by Filman. |
| Office Action dated May 13, 2015 in CN Application No. 201380025566.3. |
| Office Action dated May 14, 2018 in EP Application No. 08808111.2. |
| Office Action dated May 16, 2012 in U.S. Appl. No. 12/615,828. |
| Office Action dated May 18, 2018 in EP 14166591.9. |
| Office Action dated May 23, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
| Office Action dated May 24, 2017 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated May 25, 2021 in Japanese Office Action 2018-538073. |
| Office Action dated May 3, 2012 in CN Application No. 200880117084.X. |
| Office Action dated May 31, 2016 in U.S. Appl. No. 14/593,051 by Gross. |
| Office Action dated May 4, 2017 in CN Application No. 2014101836665. |
| Office Action dated May 5, 2015 in CN Application No. 201180006571.0. |
| Office Action dated May 7, 2015 in JP Application No. 2012-550069. |
| Office Action dated Nov. 10, 2016 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated Nov. 13, 2017 in U.S. Appl. No. 14/193,692, by Gross. |
| Office Action dated Nov. 2, 2014 in CN Application No. 201180006571.0. |
| Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/429,840 by Cabiri. |
| Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
| Office Action dated Nov. 25, 2016 in U.S. Appl. No. 13/874,017, by Cabiri. |
| Office Action dated Nov. 4, 2013 in EP Application No. 11 709 234.6. |
| Office Action dated Nov. 5, 2013 in JP Application No. 2010-527595. |
| Office Action dated Nov. 5, 2014 in U.S. Appl. No. 13/643,470 by Alon. |
| Office Action dated Nov. 8, 2017 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated Oct. 13, 2020 in Japanese Application No. 2018-538073. |
| Office Action dated Oct. 2, 2018 in JP Application No. 2018-535062 (Year: 2018). |
| Office Action dated Oct. 28, 2011 in U.S. Appl. No. 12/615,828. |
| Office Action dated Oct. 28, 2016 in CN Application No. 2014101783742. |
| Office Action dated Oct. 5, 2016 in U.S. Appl. No. 13/964,651, by Gross. |
| Office Action dated Oct. 6, 2017 in U.S. Appl. No. 14/861,478, by Cabiri. |
| Office Action dated Oct. 9, 2014 in U.S. Appl. No. 13/873,335. |
| Office Action dated Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri. |
| Office Action dated Sep. 2, 2010 in U.S. Appl. No. 12/244,688 by Gross. |
| Office Action dated Sep. 2, 2014 in JP Application No. 2012-550068. |
| Office Action dated Sep. 2, 2014 in JP Application No. 2012-550069. |
| Office Action dated Sep. 28, 2017 in IN Application No. 2528/DELNP/2010. |
| Office Action dated Sep. 29, 2013 in CN Application No. 201080040968.7. |
| Office Action dated Sep. 30, 2010 in U.S. Appl. No. 12/689,250, by Cabiri. |
| Office Action dated Sep. 30, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
| Office Action dated Sep. 6, 2011 in U.S. Appl. No. 12/345,818. |
| Office Action dated Sep. 9, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
| Office Action dated Aug. 17, 2021 in Indian Application No. 201827027625. |
| Int'l Search Report and Written Opinion dated Jul. 12, 2017 in Int'l Application No. PCT/US2016/056238. |
| Int'l Search Report and Written Opinion dated Jul. 26, 2013 in Int'l Application No. PCT/US2012/039465. |
| Int'l Search Report and Written Opinion dated Jul. 31, 2014 in Int'l Application No. PCT/US2014/033598. |
| Int'l Search Report and Written Opinion dated May 13, 2009 in Int'l Application No. PCT/IL2008/001312. |
| Int'l Search Report dated Apr. 26, 2010 in Int'l Application No. PCT/US2009/069552. |
| Int'l Search Report dated Jun. 17, 2011 in Int'l Application No. PCT/US2011/021604. |
| Int'l Search Report dated Oct. 12, 2011 in Int'l Application No. PCT/US11/21605. |
| Int'l Search Report dated Sep. 22, 2011 in Int'l Application No. PCT/IL11/00368; Written Opinion. |
| Int'l Written Opinion dated Jul. 19, 2012 in Int'l Application No. PCT/US11/21605. |
| Intel Search Report and Written Opinion dated Nov. 30, 2016 in Int'l Application No. PCT/US2016/056223. |
| International Preliminary Report on Patentability and Written Opinion dated Jul. 5, 2011 in International Application No. PCT/US2009/069552. |
| Notice of Allowance dated Aug. 24, 2015 in U.S. Appl. No. 29/479,307 by Norton. |
| Offce Action dated Sep. 21, 2010 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Apr. 22, 2016 in CN Application No. 2014102892041. |
| Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,688 by Gross. |
| Office Action dated Aug. 13, 2015 in U.S. Appl. No. 14/553,399 by Cabiri. |
| Office Action dated Aug. 14, 2017 in CN Application No. 201410178318.9. |
| Office Action dated Aug. 15, 2013 in CN Application No. 200880117084.X. |
| Office Action dated Aug. 26, 2014 in CN Application No. 201180006567.4. |
| Office Action dated Aug. 6, 2014 in EP Appl. No. 11 707 942.6. |
| Office Action dated Dec. 1, 2015 in CN Application No. 201410289204.1. |
| Office Action dated Dec. 10, 2013 in CN Application No. 201180006567.4. |
| Office Action dated Dec. 15, 2017 in U.S. Appl. No. 15/269,248, by Cabiri. |
| Office Action dated Dec. 17, 2013 in JP Application No. 2012-529808. |
| Office Action dated Dec. 4, 2017 in CN Application No. 201410178374.2. |
| Office Action dated Dec. 9, 2016 in U.S. Appl. No. 14/593,051, by Gross. |
| Office Action dated Feb. 16, 2017 in CN Application No. 2014101783189. |
| Office Action dated Feb. 21, 2012 in U.S. Appl. No. 12/689,249. |
| Office Action dated Feb. 24, 2015 in U.S. Appl. No. 14/258,661 by Cabiri. |
| Office Action dated Feb. 24, 2017 in U.S. Appl. No. 13/964,651, by Gross. |
| Office Action dated Feb. 28, 2014 in CN Application No. 201180006571.0. |
| Office Action dated Feb. 4, 2014 in EP Application No. 11 707 942.6. |
| Office Action dated Jan. 10, 2017 in U.S. Appl. No. 14/193,692, by Gross. |
| Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X. |
| Office Action dated Jan. 8, 2013 in JP Application No. 2010-527595. |
| Office Action dated Jan. 8, 2014 in U.S. Appl. No. 13/521,167 by Cabiri. |
| Office Action dated Jul. 13, 2011 in U.S. Appl. No. 12/559,563 by Cabiri. |
| Office Action dated Jul. 2, 2012 in U.S. Appl. No. 13/272,555 by Cabiri. |
| Office Action dated Jul. 28, 2020 in Japanese Application No. 2018-538074. |
| Office Action dated Jul. 3, 2017 in CN Application No. 2014101783742. |
| Office Action dated Jul. 31, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
| Office Action dated Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross. |
| Office Action dated Jun. 10, 2016 in U.S. Appl. No. 13/964,651 by Gross. |
| Office Action dated Jun. 14, 2018 in U.S. Appl. No. 13/874,121, by Degtiar. |
| Office Action dated Jun. 2, 2016 in CN Application No. 2014101783189. |
| Office Action dated Jun. 3, 2014 in JP Application No. 2010-527595. |
| Office Action dated Jun. 4, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
| Number | Date | Country | |
|---|---|---|---|
| 20200222625 A1 | Jul 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62281536 | Jan 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16071538 | US | |
| Child | 16831989 | US |
